Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/560,891	TANAKA ET AL.	
	Examiner	Art Unit	
	David K. O'Dell	1609	

All Participants:

(1) *David K. O'Dell*.

(2) *Mr. Michael R. Davis*.

Status of Application: _____

(3) _____.

(4) _____.

Date of Interview: *18 May 2007*

Time: *11:00 A.M.*

Type of Interview:
- ☒ Telephonic
- ☐ Video Conference
- ☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No
If Yes, provide a brief description:

Part I.

Rejection(s) discussed:

Claims discussed:
1

Prior art documents discussed:

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

The examiner discussed withdrawl of restriction requirement between groups I-III, and amendments to claim 1. No resolution was reached at that time, however applicant's representative wanted to have consultation with client and discuss further.

Part III.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.



(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Interview Summary	Application No.	Applicant(s)	
	10/560,891	TANAKA ET AL.	
	Examiner	Art Unit	
	David K. O'Dell	1609	

All participants (applicant, applicant's representative, PTO personnel):

(1) *David K. O'Dell*. (3)_____.

(2) *Michael R. Davis*. (4)_____.

Date of Interview: *21 May 2005*.

Type: a)☒ Telephonic b)☐ Video Conference
c)☐ Personal [copy given to: 1)☐ applicant 2)☐ applicant's representative]

Exhibit shown or demonstration conducted: d)☐ Yes e)☒ No.
If Yes, brief description: _____.

Claim(s) discussed: *1*.

Identification of prior art discussed: _____.

Agreement with respect to the claims f)☒ was reached. g)☐ was not reached. h)☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: *See Continuation Sheet*.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

_____
Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The applicant responded to the examiner's request as per claim amendments on the interview of 5/18/07, and details of such amendments were discussed, particularly the identity of n in claim 1 and various substituents R#'s. Applicant submitted claims (B-2) that needed only minor typographical corrections. The applicant stated that consulation with the inventor was required, after which an amended claim set was submitted with claim amendments making the claims commensurate in scope as per the discussion. The examiner would like to note on the record that applicant's representative Mr. Davis was very professional and patient throughout the entire process.

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record
A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews
Paragraph (b)
In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.
All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:
- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:
1) A brief description of the nature of any exhibit shown or any demonstration conducted,
2) an identification of the claims discussed,
3) an identification of the specific prior art discussed,
4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
5) a brief identification of the general thrust of the principal arguments presented to the examiner,
   (The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
6) a general indication of any other pertinent matters discussed, and
7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

Amendments to the Claims

1. (Currently amended) An epoxy compound of formula (1):



(1)

wherein n represents an integer of 1 to ~~9~~ 4,

the $-(CH_2)_n-$ group may have inserted -O- ~~, or -N(R') -~~ between the methylene groups, ~~wherein R' represents a hydrogen atom or a C_{1-18} alkyl group,~~

Z represents any one of divalent groups of the following general formulas (Z-1) to ~~(Z-6)~~ (Z-3):





wherein R^1, R^2, R^3, R^4, ~~R^5, R^6, R^7, R^8, R^9 and R^{10}~~. R^5 and R^6 are the same or different and represent independently a hydrogen ~~atom, a C_{1-18} alkyl group, an amino group substituted with one or two C_{1-18} alkyl groups, or a cyclic amino group of the following formula:~~



~~wherein m represents an integer of 4 to 12, and one methylene group or two or more not neighboring methylene groups of the C_{1-18} alkyl group or groups as defined in connection with R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9 or R^{10}, and of the cyclic amino group, may be replaced with -O-, -NH-, -N(R")- or -S-, wherein R" represents a C_{1-18} alkyl group,~~ atom or a C_{1-4} alkyl group.

Ar^1 ~~and Ar^2 are the same or different and represent any one of groups~~ is a group of the following ~~formulas (A-1) to (A-3)~~ formula (A-1), and Ar^2 is a group of the following formula (A-1) or (A-3):



(A-1)



~~(A-2)~~



(A-3)

wherein A represents a single bond and ~~or any one group selected from the group consisting of:~~



wherein R^{12}, R^{13}, R^{14}, R^{15}, ~~R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21} and R^{22}~~ R^{20} and R^{21} are the same or different and represent independently a hydrogen atom, a halogen atom, a ~~C_{1-18} alkyl~~ C_{1-4} alkyl group, a C_{1-8} alkoxy group, a cyano group, or a nitro group,

Y^1 and Y^2 ~~are the same or different and~~ each represent ~~a single bond~~, -O- ~~, -S-, or -Si(R^{23})(R^{24})-, wherein R^{23} and R^{24} are the same or different and represent independently a lower alkyl group or a phenyl group~~.

2. (Original) The epoxy compound according to claim 1, wherein Ar^1 and Ar^2 in formula (1) are the same or different and represent independently a group of the following formula:



wherein R^{25}, R^{26}, R^{27} and R^{28} are the same or different and represent independently a hydrogen atom or a methyl group.

3. (Original) The epoxy compound according to claim 1, wherein Ar^1 and Ar^2 in formula (1) represent the same group of the following formula:



wherein R^{25}, R^{26}, R^{27} and R^{28} are the same or different and represent independently a hydrogen atom or a methyl group.

4. (Previously presented) An epoxy composition, which comprises the epoxy compound as defined in claim 1 and a curing agent.

5. (Original) The epoxy composition according to claim 4, wherein the curing agent is an amine-type curing agent or a phenol type curing agent.

6. (Previously presented) A cured epoxy resin product obtained by curing the epoxy composition as defined in claim 4.

7. (Previously presented) A prepreg obtained by impregnating or coating a substrate with the epoxy composition of claim 4 and then semi-curing the epoxy composition.

8. (Previously presented) An epoxy composition, which comprises the epoxy compound as defined in claim 2 and a curing agent.

9. (Previously presented) An epoxy composition, which comprises the epoxy compound as defined in claim 3 and a curing agent.

10. (Previously presented) A cured epoxy resin product obtained by curing the epoxy composition as defined in claim 5.

11. (Previously presented) A prepreg obtained by impregnating or coating a substrate with the epoxy composition of claim 5 and then semi-curing the epoxy composition.

Michael R. Davis
Matthew M. Jacob
Warren M. Cheek, Jr.
Nils E. Pedersen
Charles R. Watts
Michael S. Huppert
Jeffrey R. Filipek
W. Douglas Hahm

David M. Ovedovitz
Joseph M. Gorski*
Jonathan R. Bowser*
Jay F. Williams*
Amy E. Pulliam*
Kenneth Fields*
Carl Pledger*

OF COUNSEL:
John T. Miller

*Member of Bar other than D.C.

WENDEROTH, LIND & PONACK, L.L.P.

Attorneys and Counselors at Law
Patents, Trademarks and Copyrights
2033 K Street, N.W., Suite 800
Washington, D. C. 20006-1021 U.S.A.

E. F. Wenderoth (1886-1974)
John E. Lind (1892-1983)
A. Ponack (1900-1969)

TELEPHONE:
202-721-8200

FACSIMILE:
202-721-8250 (G-III)
202-833-3015 (G-IV)

E-MAIL:
wlp@wenderoth.com

INTERNET:
www.wenderoth.com

FACSIMILE COVER SHEET

DATE: June 5, 2007

TO: **Examiner David K. Odell/Rita Desai**
Group Art Unit 1609 Fax No.: (571) 273-0684

Confirmation No. 3651

FROM: Michael R. Davis

Number of pages being transmitted, including this cover sheet: 9

Please direct all questions concerning the transmittal of these pages to Patricia Hill.

RE: Serial No. 10/560,891 (Shinya TANAKA et al.), filed January 20, 2006

MESSAGE:

Referring to our recent telephone discussions/voicemails, I am enclosing a formal Supplemental Preliminary Amendment adopting all of the changes that we agreed upon.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of	:	**Confirmation No. 3651**
Shinya TANAKA et al.	:	Attorney Docket No. 2005_1857A
Serial No. 10/560,891	:	Group Art Unit 1609
Filed January 20, 2006	:	Examiner David K. Odell
EPOXY COMPOUND AND CURED EPOXY RESIN PRODUCT	:	**Mail Stop Amendment**

SUPPLEMENTAL PRELIMINARY AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975.

Sir:

Kindly amend the above-identified application as follows:

Amendments to the Specification

Page 18, please replace the paragraph spanning line 9 through page 19, line 6 with the following rewritten paragraph:

The reaction of the alcohol compound (2) with the compound (3) is carried out generally by mixing both compounds in a solvent in the presence of a base, and said mixing may be conducted in an optional order. The solvent that may be used is not particularly limited as far as it is inert to the reaction, but from a viewpoint of easy suppression of byproduct formation, a hydrophilic solvent is preferable. Examples of the hydrophilic solvent include alcohol type solvents such as methanol, ethanol, propanol, butanol, ethylene glycol, and propylene glycol, ketone type solvents such as methyl ethyl ketone or methyl isobutyl ketone, non-protonic polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, or N-methylpyrrolidone, ether type solvents such as tetrahydrofuran, dioxane, methoxymethyl ether, or diethoxyethane, and mixtures thereof. Inter alia, ether type solvents, ~~non-protonic~~ aprotic polar solvents, and a mixture thereof are preferable. ~~Non-protonic~~ Aprotic polar solvents are more preferable and, inter alia, dimethyl sulfoxide is particularly preferable. An amount of the solvent that may be used is generally 0.1 to 50 parts by weight, preferably 0.5 to 5 parts by weight per part by weight of the alcohol compound (2).

Page 21, please replace the paragraph spanning line 24 through page 22, line 4 with the following rewritten paragraph:

After ~~eoxidation~~ epoxidation by the oxidizing agent, the remaining oxidizing agent is decomposed if necessary, followed by concentration, to separate the epoxy compound (1). The separated epoxy compound (1) may be further purified by a conventional purification means, for example, by recrystallization.

Amendments to the Claims

1. (Currently amended) An epoxy compound of formula (1):



(1)

wherein n represents an integer of 1 to ~~9~~ 4,

the $-(CH_2)_n-$ group may have inserted -O- ~~, or -N(R') -~~ between the methylene groups, ~~wherein R' represents a hydrogen atom or a C_{1-18} alkyl group;~~

Z represents any one of divalent groups of the following general formulas (Z-1) to ~~(Z-6)~~ (Z-3):





wherein R^1, R^2, R^3, R^4, ~~R^5, R^6, R^7, R^8, R^9 and R^{10}~~. R^5 and R^6 are the same or different and represent independently a hydrogen ~~atom, a C_{1-18} alkyl group, an amino group substituted with one or two C_{1-18} alkyl groups, or a cyclic amino group of the following formula:~~



~~wherein m represents an integer of 4 to 12, and one methylene group or two or more not neighboring methylene groups of the C_{1-18} alkyl group or groups as defined in connection with R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9 or R^{10}, and of the cyclic amino group, may be replaced with -O-, -NH-, -N(R")- or -S-, wherein R" represents a C_{1-18} alkyl group,~~ atom or a C_{1-4} alkyl group.

Ar^1 ~~and Ar^2 are the same or different and represent any one of groups~~ is a group of the following ~~formulas (A-1) to (A-3)~~ formula (A-1), and Ar^2 is a group of the following formula (A-1) or (A-3):



(A-1)



~~(A-2)~~



(A-3)

wherein A represents a single bond and ~~or any one group selected from the group consisting of:~~



wherein R^{12}, R^{13}, R^{14}, R^{15}, ~~R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21} and R^{22}~~ R^{20} and R^{21} are the same or different and represent independently a hydrogen atom, a halogen atom, a ~~C_{1-18} alkyl~~ C_{1-4} alkyl group, a C_{1-8} alkoxy group, a cyano group, or a nitro group,

Y^1 and Y^2 ~~are the same or different and~~ each represent ~~a single bond~~, -O- ~~, -S-, or -Si(R^{23})(R^{24})-, wherein R^{23} and R^{24} are the same or different and represent independently a lower alkyl group or a phenyl group~~.

2. (Original) The epoxy compound according to claim 1, wherein Ar^1 and Ar^2 in formula (1) are the same or different and represent independently a group of the following formula:



wherein R^{25}, R^{26}, R^{27} and R^{28} are the same or different and represent independently a hydrogen atom or a methyl group.

3. (Original) The epoxy compound according to claim 1, wherein Ar^1 and Ar^2 in formula (1) represent the same group of the following formula:



wherein R^{25}, R^{26}, R^{27} and R^{28} are the same or different and represent independently a hydrogen atom or a methyl group.

4. (Previously presented) An epoxy composition, which comprises the epoxy compound as defined in claim 1 and a curing agent.

5. (Original) The epoxy composition according to claim 4, wherein the curing agent is an amine-type curing agent or a phenol type curing agent.

6. (Previously presented) A cured epoxy resin product obtained by curing the epoxy composition as defined in claim 4.

7. (Previously presented) A prepreg obtained by impregnating or coating a substrate with the epoxy composition of claim 4 and then semi-curing the epoxy composition.

8. (Previously presented) An epoxy composition, which comprises the epoxy compound as defined in claim 2 and a curing agent.

9. (Previously presented) An epoxy composition, which comprises the epoxy compound as defined in claim 3 and a curing agent.

10. (Previously presented) A cured epoxy resin product obtained by curing the epoxy composition as defined in claim 5.

11. (Previously presented) A prepreg obtained by impregnating or coating a substrate with the epoxy composition of claim 5 and then semi-curing the epoxy composition.

Remarks

Substance of Interview

During a telephone discussion with the Examiner on May 18, 2007, the Examiner informed Applicants' attorney that he was rejoining Groups II and III (Office Action of April 6, 2007) with elected Group I. The Examiner further indicated that each of Groups I-V should indicate that $Y^1 = Y^2 = O$ (instead of $Y^2 = Y^2 = O$); that Groups II and III should indicate that Ar^2 is phenyl or biphenyl; and that Group V should include all of the compounds other than those defined in Groups I-IV. The Examiner then proposed amendments to place the application in condition for allowance, and further proposed correction of spelling errors on pages 18, 19 and 21 of the specification.

After further discussions with the Examiner about the scope of allowable claims, and faxing proposals for amending the claims to the Examiner, an agreement was reached on the scope of the claims to be allowed. Referring to Proposed Claim Sets A-1, A-2, B-1 and B-2, faxed to the Examiner on May 25, 2007, it was agreed that Applicants would amend the claims as in claim set B-2 except that Z would refer to (Z-1) to (Z-3), and the word "like." (a clerical error) after claim 7 would be deleted.

Amendments

Claim 1 has now been amended as agreed upon. That is, claim 1 as set forth above is of the same scope as claim 1 in claim set B-2, with Z referring only to (Z-1) to (Z-3).

The spelling errors pages 18, 19 and 21 as noted by the Examiner, have been corrected as suggested by the Examiner.

Applicants emphasize that the foregoing amendments are without prejudice to their rights under 35 U.S.C. §121 to file a divisional application for the subject matter which has been deleted from the present claims.

The application is now considered to be in condition for allowance, and such allowance is solicited.

Respectfully submitted,

Shinya TANAKA et al.

By: 

Michael R. Davis
Registration No. 25,134
Attorney for Applicants

MRD/pth
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
June 5, 2007

10560891

Element Count :
Node 18: Limited
C,C4-5
N,N1-2

L9 STRUCTURE UPLOADED

=> d l9
L9 HAS NO ANSWERS
L9 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l9
SAMPLE SEARCH INITIATED 16:24:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 7347 TO ITERATE

27.2% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 141802 TO 152078
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L9

=> s l9 full
FULL SEARCH INITIATED 16:25:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 145946 TO ITERATE

100.0% PROCESSED 145946 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.01

L11 13 SEA SSS FUL L9

=> d scan

10560891

L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenamine, 4,4'-methylenebis-, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI)
MF (C35 H29 N O6 . C13 H14 N2)x
CI PMS

CM 1

PAGE 1-A



PAGE 2-A



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20

L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenamine, 4,4'-methylenebis-, polymer with 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-

10560891

(oxiranylmethoxy)phenoxy]pyridine (9CI)
MF (C29 H25 N O6 . C13 H14 N2)x
CI PMS

CM 1



CM 2



L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenamine, 4,4'-methylenebis-, polymer with 2,6-bis[[4'-[2-(oxiranylmethoxy)ethoxy][1,1'-biphenyl]-4-yl]oxy]pyridine (9CI)
MF (C39 H37 N O8 . C13 H14 N2)x
CI PMS

CM 1

PAGE 1-A



PAGE 2-A



CM 2



L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pyridine, 2,6-bis[[4'-[1-(oxiranylmethoxy)ethyl][1,1'-biphenyl]-4-yl]oxy]-(9CI)
MF C39 H37 N O6
CI COM

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Guanidine, cyano-, polymer with 2,6-bis[[4'-[1-(oxiranylmethoxy)ethyl][1,1'-biphenyl]-4-yl]oxy]pyridine (9CI)
MF (C39 H37 N O6 . C2 H4 N4)x
CI PMS

CM 1

PAGE 1-A



PAGE 2-A



CM 2



L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pyridazine, 3,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI)
MF C34 H28 N2 O6

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 13 ANSWERS . REGISTRY COPYRIGHT 2007 ACS on STN
IN Pyridine, 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]- (9CI)
MF C29 H25 N O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,5-Naphthalenediamine, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI)
MF (C35 H29 N O6 . C10 H10 N2)x
CI PMS

10560891

CM 1

PAGE 1-A



PAGE 2-A



CM 2



L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pyridine, 2,6-bis[[4'-[2-(oxiranylmethoxy)ethoxy][1,1'-biphenyl]-4-yl]oxy]-
(9CI)
MF C39 H37 N O8
CI COM

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Guanidine, cyano-, polymer with 2,6-bis[[4'-[2-(oxiranylmethoxy)ethoxy][1,1'-biphenyl]-4-yl]oxy]pyridine (9CI)
MF (C39 H37 N O8 . C2 H4 N4)x
CI PMS

CM 1

PAGE 1-A



PAGE 2-A



CM 2



L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Methanediamine, N,N'-dimethyl-, polymer with 2,6-bis[[4'-[1-(oxiranylmethoxy)ethyl][1,1'-biphenyl]-4-yl]oxy]pyridine (9CI)
MF (C39 H37 N O6 . C3 H10 N2)x
CI PMS

CM 1

PAGE 1-A



PAGE 2-A



CM 2



L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pyridine, 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI)
MF C35 H29 N O6
CI COM

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pyrimidine, 4-methyl-2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI)
MF C35 H30 N2 O6

PAGE 1-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 345.10 | 523.44

FILE 'CAPLUS' ENTERED AT 16:25:20 ON 16 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 May 2007 VOL 146 ISS 21
FILE LAST UPDATED: 15 May 2007 (20070515/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

(FILE 'HOME' ENTERED AT 15:57:48 ON 16 MAY 2007)

FILE 'REGISTRY' ENTERED AT 15:58:01 ON 16 MAY 2007
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 2 S L1 FULL

FILE 'STNGUIDE' ENTERED AT 16:00:18 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 16:02:24 ON 16 MAY 2007
L4 STRUCTURE UPLOADED
L5 0 S L4

FILE 'STNGUIDE' ENTERED AT 16:05:42 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 16:22:53 ON 16 MAY 2007
L6 STRUCTURE UPLOADED
L7 0 S L6
L8 3 S L6 FULL

10560891

L9 STRUCTURE UPLOADED
L10 0 S L9
L11 13 S L9 FULL

FILE 'CAPLUS' ENTERED AT 16:25:20 ON 16 MAY 2007

=> s l11
L12 3 L11

=> d cbib abs hitstr 1-3

L12 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
2006:1030337 Document No. 145:378329 Epoxy compounds having alkylene ether chains and low melting point and their resin cured products. Hibino, Hiroaki; Inoue, Kazuya (Sumitomo Chemical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 2006265110 A 20061005, 24pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 2005-81361 20050322.

AB The compds. are represented by GyZAr1X1YX2Ar2ZGy [Gy = glycidyl; X1, X2 = O, single bond, CO2; Y = C1-18 linear alkylene, R1- and R2-disubstituted pyridinediyl; R1, R2 = H, C1-18 alkyl; Z = C2-18 branched linear alkylene; Ar1, Ar2 = R3R4C6H2AC6H2R5R6 [A = single bond, CR7:CH, C.tplbond.C, CH:N, OCO; R3-R7 = H, halo, C1-8 alkyl(oxy), cyano, nitro]]. Compns. of the compds. and their hardeners, their cured products, and B-staged prepregs therefrom are also claimed. Thus, 4-hydroxy-4'-acetylbiphenyl was reacted with 1,2-bis(2-chloroethoxy)ethane in the presence of NaOH to give 1,8-bis[4-(4-acetylphenyl)phenoxy]-3,6-dioxaoctane, which was reacted with NaBH4 at 50° and then with HCl to give 1,8-bis[4-[4-(1-hydroxyethyl)phenyl]phenoxy]-3,6-dioxaoctane (I). Then, I was reacted with epichlorohydrin at 50° in the presence of Bu4NBr to give 1,8-bis[4-[4-(3-oxiranyl-1-methyl-2-oxapropyl)phenyl]phenoxy]-3,6-dioxaoctane in 75% yield and purity 98%, 100 parts of which was formulated with dimethyldiaminomethane to show curing temperature 170°.

IT **910792-68-6P**
RL: IMF (Industrial manufacture); RCT (Reactant); TEM (Technical or engineered material use); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(low-m.p. epoxy compds. having alkylene chains and good handling property for forming prepregs)

RN 910792-68-6 CAPLUS
CN Pyridine, 2,6-bis[[4'-[1-(oxiranylmethoxy)ethyl][1,1'-biphenyl]-4-yl]oxy]-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **910792-73-3P 910792-74-4P**
RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(low-m.p. epoxy compds. having alkylene chains and good handling property for forming prepregs)

RN 910792-73-3 CAPLUS

CN Methanediamine, N,N'-dimethyl-, polymer with 2,6-bis[[4'-[1-(oxiranylmethoxy)ethyl][1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 910792-68-6
CMF C39 H37 N O6

PAGE 1-A



PAGE 2-A



CM 2

CRN 4410-94-0
CMF C3 H10 N2

$H_3C-NH-CH_2-NH-CH_3$

RN 910792-74-4 CAPLUS
CN Guanidine, cyano-, polymer with 2,6-bis[[4'-[1-(oxiranylmethoxy)ethyl][1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 910792-68-6
CMF C39 H37 N O6

PAGE 1-A



PAGE 2-A



CM 2

CRN 461-58-5
CMF C2 H4 N4



L12 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
2006:627670 Document No. 145:84084 Epoxy compounds, compositions containing them, cured epoxy resins therefrom, and prepregs containing them. Hibino, Hiroaki; Tanaka, Shinya (Sumitomo Chemical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 2006169425 A 20060629, 17 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 2004-365798 20041217.

AB The epoxy compds. GZOAr1OQOAr2OZG [G = glycidyl; Q = R1- and R2-substituted pyridinediyl; R1, R2 = H, C1-18 alkyl; Ar1, Ar2 = (un)substituted biphenylene, (un)substituted naphthalenediyl; Z = branched C2-18 alkylene, C2-18 alkylene whose ≥1 C-C single bond is

substituted by O], which can be induced to liquid-crystalline epoxy resin cured products, are prepared Thus, 630 parts 4,4'-biphenol was treated with 100 parts 2,6-dichloropyridine at 120° in DMSO in the presence of NaOH to give 159 parts 2,6-bis[4-(4-hydroxyphenyl)phenoxy]pyridine, 100 parts of which was treated with 110 parts 2-(2-chloroethoxy)tetrahydro-2H-pyran at 80° in DMSO in the presence of KOH and Bu4NBr to give 67.1 parts 2,6-bis[4-[4-(2-hydroxyethoxy)phenyl]phenoxy]pyridine (I). Then, 100 parts I was treated with 860 parts epichlorohydrin in the presence of NaOH and Et4NCl to give 110.8 parts 2,6-bis[4-[4-[2-(oxiranylmethoxy)ethoxy]phenyl]phenoxy]pyridine, 20 parts of which was mixed with 3 parts 4,4'-diaminodiphenylmethane and heated to give a liquid-crystalline cured product having good thermal conductivity

IT **893418-58-1P 893418-59-2P**
RL: IMF (Industrial manufacture); PRP (Properties); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(pyridine-based epoxy resins for liquid-crystalline cured products)

RN 893418-58-1 CAPLUS

CN Benzenamine, 4,4'-methylenebis-, polymer with 2,6-bis[[4'-[2-(oxiranylmethoxy)ethoxy][1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 893418-57-0
CMF C39 H37 N O8

PAGE 1-A



PAGE 2-A



CM 2

CRN 101-77-9
CMF C13 H14 N2



RN 893418-59-2 CAPLUS
CN Guanidine, cyano-, polymer with 2,6-bis[[4'-[2-(oxiranylmethoxy)ethoxy][1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 893418-57-0
CMF C39 H37 N O8

PAGE 1-A



PAGE 2-A



CM 2

CRN 461-58-5
CMF C2 H4 N4



IT **893418-57-0P**
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(pyridine-based epoxy resins for liquid-crystalline cured products)
RN 893418-57-0 CAPLUS
CN Pyridine, 2,6-bis[[4'-[2-(oxiranylmethoxy)ethoxy][1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A





L12 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
2004:1154700 Document No. 142:75325 Epoxy compound and amine-cured epoxy resin product. Tanaka, Shinya; Takezawa, Yoshitaka; Takahashi, Hiroyuki (Sumitomo Chemical Company, Limited, Japan; Hitachi, Ltd.). PCT Int. Appl. WO 2004113327 A1 20041229, 64 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-JP8934 20040618. PRIORITY: JP 2003-174545 20030619.

AB The epoxy compound, which can be converted into a cured epoxy resin product having liquid crystal properties is obtained by curing with amine (or phenol) curing agent. Since the cured epoxy resin product exhibits good heat conductivity, it is also useful as an insulating material requiring high heat releasability such as a printed circuit substrate and the like. An example resin precursor 2,6-bis[4-[4-(oxiranylmethoxy)phenyl]phenoxy]pyridine had m.p. 157-160°.

IT **815600-49-8P 815600-51-2P 815600-53-4P**
815600-56-7P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and curing; pyridine condensate epoxy compound and cured epoxy resin product)

RN 815600-49-8 CAPLUS

CN Pyridine, 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 815600-51-2 CAPLUS
CN Pyridazine, 3,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 815600-53-4 CAPLUS
CN Pyrimidine, 4-methyl-2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 815600-56-7 CAPLUS
CN Pyridine, 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



IT **815600-57-8P 815600-58-9P 815600-59-0P**
RL: IMF (Industrial manufacture); PRP (Properties); PREP (Preparation)
(pyridine condensate epoxy compound and cured epoxy resin product)
RN 815600-57-8 CAPLUS
CN Benzenamine, 4,4'-methylenebis-, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 815600-49-8
CMF C35 H29 N O6

PAGE 1-A



PAGE 2-A



CM 2

CRN 101-77-9
CMF C13 H14 N2



RN 815600-58-9 CAPLUS
CN 1,5-Naphthalenediamine, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 815600-49-8
CMF C35 H29 N O6

PAGE 1-A



PAGE 2-A



CM 2

CRN 2243-62-1
CMF C10 H10 N2



RN 815600-59-0 CAPLUS
CN Benzenamine, 4,4'-methylenebis-, polymer with 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]pyridine (9CI) (CA INDEX NAME)

CM 1

10560891

CRN 815600-56-7
CMF C29 H25 N O6



CM 2

CRN 101-77-9
CMF C13 H14 N2



=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.28	539.72

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

FILE 'STNGUIDE' ENTERED AT 16:26:02 ON 16 MAY 2007

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 11, 2007 (20070511/UP).

=>

10560891

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptadko1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JAN 08  CHEMLIST enhanced with New Zealand Inventory of Chemicals
 NEWS  3  JAN 16  CA/CAplus Company Name Thesaurus enhanced and reloaded
 NEWS  4  JAN 16  IPC version 2007.01 thesaurus available on STN
 NEWS  5  JAN 16  WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
 NEWS  6  JAN 22  CA/CAplus updated with revised CAS roles
 NEWS  7  JAN 22  CA/CAplus enhanced with patent applications from India
 NEWS  8  JAN 29  PHAR reloaded with new search and display fields
 NEWS  9  JAN 29  CAS Registry Number crossover limit increased to 300,000 in
                  multiple databases
 NEWS 10  FEB 15  PATDPASPC enhanced with Drug Approval numbers
 NEWS 11  FEB 15  RUSSIAPAT enhanced with pre-1994 records
 NEWS 12  FEB 23  KOREAPAT enhanced with IPC 8 features and functionality
 NEWS 13  FEB 26  MEDLINE reloaded with enhancements
 NEWS 14  FEB 26  EMBASE enhanced with Clinical Trial Number field
 NEWS 15  FEB 26  TOXCENTER enhanced with reloaded MEDLINE
 NEWS 16  FEB 26  IFICDB/IFIPAT/IFIUDB reloaded with enhancements
 NEWS 17  FEB 26  CAS Registry Number crossover limit increased from 10,000
                  to 300,000 in multiple databases
 NEWS 18  MAR 15  WPIDS/WPIX enhanced with new FRAGHITSTR display format
 NEWS 19  MAR 16  CASREACT coverage extended
 NEWS 20  MAR 20  MARPAT now updated daily
 NEWS 21  MAR 22  LWPI reloaded
 NEWS 22  MAR 30  RDISCLOSURE reloaded with enhancements
 NEWS 23  APR 02  JICST-EPLUS removed from database clusters and STN
 NEWS 24  APR 30  GENBANK reloaded and enhanced with Genome Project ID field
 NEWS 25  APR 30  CHEMCATS enhanced with 1.2 million new records
 NEWS 26  APR 30  CA/CAplus enhanced with 1870-1889 U.S. patent records
 NEWS 27  APR 30  INPADOC replaced by INPADOCDB on STN
 NEWS 28  MAY 01  New CAS web site launched
 NEWS 29  MAY 08  CA/CAplus Indian patent publication number format defined
 NEWS 30  MAY 14  RDISCLOSURE on STN Easy enhanced with new search and display
                  fields
 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

10560891

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:32:41 ON 16 MAY 2007

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:33:10 ON 16 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2
DICTIONARY FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10560891_resin.str

chain nodes :
1 9
ring/chain nodes :
2 3 5 6 11 12
chain bonds :
1-2 1-3 5-9 9-11

10560891

2. An Ak node attached to another Ak node.

```
=> FIL STNGUIDE
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                               ENTRY    SESSION
FULL ESTIMATED COST                             2.70       2.91

FILE 'STNGUIDE' ENTERED AT 14:36:46 ON 16 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 11, 2007 (20070511/UP).

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                               ENTRY    SESSION
FULL ESTIMATED COST                             0.06       2.97

FILE 'REGISTRY' ENTERED AT 14:37:38 ON 16 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 MAY 2007  HIGHEST RN 934804-03-2
DICTIONARY FILE UPDATES:  15 MAY 2007  HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\1560891resin.str
```

10560891





```
chain nodes :
1  9
ring/chain nodes :
2  3  5  6  11  12
chain bonds :
1-2  1-3  5-9  9-11
ring/chain bonds :
2-5  3-6  11-12
exact/norm bonds :
1-2  1-3  2-5  3-6  11-12
exact bonds :
5-9  9-11


Match level :
1:Atom  2:CLASS  3:CLASS  5:Atom  6:Atom  9:Atom  11:CLASS  12:CLASS
Generic attributes :
5:
Saturation              : Unsaturated
Number of Carbon Atoms  : less than 7
Type of Ring System     : Monocyclic
6:
Saturation              : Unsaturated
Type of Ring System     : Monocyclic
9:
Saturation              : Unsaturated
Number of Carbon Atoms  : less than 7
Type of Ring System     : Monocyclic

Element Count :
Node 1: Limited
    C,C4-5
    N,N1-2

Node 5: Limited
    C,C6

Node 6: Limited
    C,C6

Node 9: Limited
    C,C6
```

L2 STRUCTURE UPLOADED

```
=> d l2
L2 HAS NO ANSWERS
L2              STR
```

10560891



Structure attributes must be viewed using STN Express query preparation.

=> s l2
GENERIC GROUP NOT VALID HERE
Generic groups may not be used in these circumstances:

1. Any generic group node (e.g., Hy) in a ring.
2. An Ak node attached to another Ak node.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.45	3.42

FILE 'STNGUIDE' ENTERED AT 14:38:22 ON 16 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 11, 2007 (20070511/UP).

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.54	3.96

FILE 'REGISTRY' ENTERED AT 14:44:02 ON 16 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2
DICTIONARY FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

10560891

Uploading C:\Program Files\Stnexp\Queries\10560891blah.str



chain nodes :
1 2 3 4 5 6 7
ring nodes :
12 13 14
chain bonds :
1-2 1-3 2-4 3-5 4-6 6-7
ring bonds :
12-13 12-14 13-14
exact/norm bonds :
1-2 1-3 12-13 12-14 13-14
exact bonds :
2-4 3-5 4-6 6-7

Match level :
1:Atom 2:CLASS 3:CLASS 4:Atom 5:Atom 6:Atom 7:CLASS 12:Atom 13:Atom
14:Atom
Generic attributes :
1:
Saturation : Unsaturated
4:
Saturation : Unsaturated
5:
Saturation : Unsaturated
6:
Saturation : Unsaturated

Element Count :
Node 1: Limited
C,C4-5
N,N1-2

Node 4: Limited
C,C3

Node 5: Limited
C,C6

Node 6: Limited
C,C6

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR

10560891



Structure attributes must be viewed using STN Express query preparation.

```
=> s l3
SAMPLE SEARCH INITIATED 14:44:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   174377 TO ITERATE

  1.1% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      3462969 TO  3512111
PROJECTED ANSWERS:               0 TO        0

L4            0 SEA SSS SAM L3

=> s l3 full
FULL SEARCH INITIATED 14:44:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  3496598 TO ITERATE

 28.4% PROCESSED   993395 ITERATIONS                                0 ANSWERS

 28.6% PROCESSED  1000000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.17

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      3496598 TO  3496598
PROJECTED ANSWERS:               0 TO        0

L5            0 SEA SSS FUL L3

=> FIL STNGUIDE
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             172.55     176.51

FILE 'STNGUIDE' ENTERED AT 14:45:20 ON 16 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 11, 2007 (20070511/UP).
```

10560891

=> FIL REGISTRY
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.36	176.87

FILE 'REGISTRY' ENTERED AT 14:49:07 ON 16 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2
DICTIONARY FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10560891resinc.str



chain nodes :
7 9 10 13 14
ring nodes :
1 2 3 4 5 6 15 16 17
chain bonds :
7-9 9-10 10-13 13-14 14-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-17 16-17
exact/norm bonds :
13-14 15-16 15-17 16-17
exact bonds :
7-9 9-10 10-13 14-15
normalized bonds :

10560891

1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom
Generic attributes :
9:
Saturation : Unsaturated
10:
Saturation : Unsaturated

Element Count :
Node 9: Limited
C,C6

Node 10: Limited
C,C6

L6 STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l6
SAMPLE SEARCH INITIATED 14:49:24 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1263 TO ITERATE

100.0% PROCESSED 1263 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

10560891

BATCH **COMPLETE**
PROJECTED ITERATIONS: 23128 TO 27392
PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

=> s l7 full
FULL SEARCH INITIATED 14:49:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 24932 TO ITERATE

100.0% PROCESSED 24932 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.02

L8 5 SEA SSS FUL L6

=> d scan

L8 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenamine, 4,4'-methylenebis-, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI)
MF (C35 H29 N O6 . C13 H14 N2)x
CI PMS

CM 1







CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenamine, 4,4'-methylenebis-, polymer with 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]pyridine (9CI)
MF (C29 H25 N O6 . C13 H14 N2)x
CI PMS

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pyridine, 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]- (9CI)
MF C29 H25 N O6
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,5-Naphthalenediamine, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI)
MF (C35 H29 N O6 . C10 H10 N2)x
CI PMS

CM 1

PAGE 1-A



PAGE 2-A



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pyridine, 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI)
MF C35 H29 N O6
CI COM

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> 1
1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.55	349.42

FILE 'CAPLUS' ENTERED AT 14:50:31 ON 16 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

10560891

FILE COVERS 1907 - 16 May 2007 VOL 146 ISS 21
FILE LAST UPDATED: 15 May 2007 (20070515/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

(FILE 'HOME' ENTERED AT 14:32:41 ON 16 MAY 2007)

FILE 'REGISTRY' ENTERED AT 14:33:10 ON 16 MAY 2007
L1 STRUCTURE UPLOADED

FILE 'STNGUIDE' ENTERED AT 14:36:46 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 14:37:38 ON 16 MAY 2007
L2 STRUCTURE UPLOADED

FILE 'STNGUIDE' ENTERED AT 14:38:22 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 14:44:02 ON 16 MAY 2007
L3 STRUCTURE UPLOADED
L4 0 S L3
L5 0 S L3 FULL

FILE 'STNGUIDE' ENTERED AT 14:45:20 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 14:49:07 ON 16 MAY 2007
L6 STRUCTURE UPLOADED
L7 0 S L6
L8 5 S L7 FULL

FILE 'CAPLUS' ENTERED AT 14:50:31 ON 16 MAY 2007

=> s l8
L9 1 L8

=> d cbib abs hitstr

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
2004:1154700 Document No. 142:75325 Epoxy compound and amine-cured epoxy resin product. Tanaka, Shinya; Takezawa, Yoshitaka; Takahashi, Hiroyuki (Sumitomo Chemical Company, Limited, Japan; Hitachi, Ltd.). PCT Int. Appl. WO 2004113327 A1 20041229, 64 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR.

(English). CODEN: PIXXD2. APPLICATION: WO 2004-JP8934 20040618.
PRIORITY: JP 2003-174545 20030619.

AB The epoxy compound, which can be converted into a cured epoxy resin product having liquid crystal properties is obtained by curing with amine (or phenol) curing agent. Since the cured epoxy resin product exhibits good heat conductivity, it is also useful as an insulating material requiring high heat releasability such as a printed circuit substrate and the like. An example resin precursor 2,6-bis[4-[4-(oxiranylmethoxy)phenyl]phenoxy]pyridine had m.p. 157-160°.

IT **815600-49-8P 815600-56-7P**
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and curing; pyridine condensate epoxy compound and cured epoxy resin product)

RN 815600-49-8 CAPLUS
CN Pyridine, 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 815600-56-7 CAPLUS
CN Pyridine, 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



IT **815600-57-8P 815600-58-9P 815600-59-0P**
RL: IMF (Industrial manufacture); PRP (Properties); PREP (Preparation)
(pyridine condensate epoxy compound and cured epoxy resin product)
RN 815600-57-8 CAPLUS
CN Benzenamine, 4,4'-methylenebis-, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 815600-49-8
CMF C35 H29 N O6





PAGE 2-A



CM 2

CRN 101-77-9
CMF C13 H14 N2



RN 815600-58-9 CAPLUS
CN 1,5-Naphthalenediamine, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 815600-49-8
CMF C35 H29 N O6

PAGE 1-A







CM 2

CRN 2243-62-1
CMF C10 H10 N2



RN 815600-59-0 CAPLUS
CN Benzenamine, 4,4'-methylenebis-, polymer with 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 815600-56-7
CMF C29 H25 N O6



CM 2

CRN 101-77-9
CMF C13 H14 N2

10560891



=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.15	356.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-0.78

FILE 'STNGUIDE' ENTERED AT 14:52:57 ON 16 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 11, 2007 (20070511/UP).

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	356.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.78

FILE 'REGISTRY' ENTERED AT 14:57:15 ON 16 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2
DICTIONARY FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10560891alcohol.str

10560891





chain nodes :
7 9 10 13 14
ring nodes :
1 2 3 4 5 6
chain bonds :
7-9 9-10 10-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact bonds :
7-9 9-10 10-13 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
13:CLASS 14:CLASS
Generic attributes :
9:
Saturation : Unsaturated
10:
Saturation : Unsaturated

Element Count :
Node 9: Limited
C,C6

Node 10: Limited
C,C6

L10 STRUCTURE UPLOADED

=> d l10
L10 HAS NO ANSWERS
L10 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l10
SAMPLE SEARCH INITIATED 14:57:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   165362 TO ITERATE

  1.2% PROCESSED     2000 ITERATIONS                                  0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      3283288 TO  3331192
PROJECTED ANSWERS:               0 TO        0

L11           0 SEA SSS SAM L10

=> s l10 full
FULL SEARCH INITIATED 14:57:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  3308614 TO ITERATE

 29.9% PROCESSED   989187 ITERATIONS  (     1 INCOMPLETE)         4 ANSWERS

 30.2% PROCESSED  1000000 ITERATIONS  (     1 INCOMPLETE)         4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.17

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      3308614 TO  3308614
PROJECTED ANSWERS:               4 TO       23

L12           4 SEA SSS FUL L10

=>  dscan
DSCAN IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d scan

L12  4 ANSWERS   REGISTRY  COPYRIGHT 2007 ACS on STN
IN   [1,1'-Biphenyl]-4-ol, 3-methoxy-4'-[[2-(1H-tetrazol-5-yl)thieno[2,3-
     c]pyridin-4-yl]oxy]- (9CI)
MF   C21 H15 N5 O3 S
```

10560891



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L12 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
ITERATION INCOMPLETE
IN Poly[spiro[2H-isoindolium-2,7'-[1,4,10,13]tetraoxa[16]aza[7]azoniacyclooctadecane]-16',16':5,6-tetrayl-5,6-bis(methylene)] (9CI)
MF (C22 H34 N2 O4)n
CI PMS, COM



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L12 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-ol, 4'-[(6-chloro-2-pyridinyl)oxy]- (9CI)
MF C17 H12 Cl N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   174.35     531.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -0.78

FILE 'CAPLUS' ENTERED AT 15:00:41 ON 16 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 16 May 2007  VOL 146 ISS 21
FILE LAST UPDATED: 15 May 2007  (20070515/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

     (FILE 'HOME' ENTERED AT 14:32:41 ON 16 MAY 2007)

     FILE 'REGISTRY' ENTERED AT 14:33:10 ON 16 MAY 2007
L1             STRUCTURE UPLOADED

     FILE 'STNGUIDE' ENTERED AT 14:36:46 ON 16 MAY 2007

     FILE 'REGISTRY' ENTERED AT 14:37:38 ON 16 MAY 2007
L2             STRUCTURE UPLOADED

     FILE 'STNGUIDE' ENTERED AT 14:38:22 ON 16 MAY 2007

     FILE 'REGISTRY' ENTERED AT 14:44:02 ON 16 MAY 2007
L3             STRUCTURE UPLOADED
L4           0 S L3
L5           0 S L3 FULL

     FILE 'STNGUIDE' ENTERED AT 14:45:20 ON 16 MAY 2007

     FILE 'REGISTRY' ENTERED AT 14:49:07 ON 16 MAY 2007
L6             STRUCTURE UPLOADED
L7           0 S L6
L8           5 S L7 FULL

     FILE 'CAPLUS' ENTERED AT 14:50:31 ON 16 MAY 2007
L9           1 S L8
```

10560891

FILE 'STNGUIDE' ENTERED AT 14:52:57 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 14:57:15 ON 16 MAY 2007
L10 STRUCTURE UPLOADED
L11 0 S L10
L12 4 S L10 FULL

FILE 'CAPLUS' ENTERED AT 15:00:41 ON 16 MAY 2007

=> s l12
L13 2 L12

=> d scan

L13 2 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
IC ICM C07D405-14
CC 37-3 (Plastics Manufacture and Processing)
Section cross-reference(s): 38, 76
TI Epoxy compound and amine-cured epoxy resin product
ST epoxy resin liq cryst cured insulator circuit board; biphenylene pyridindiyl diglycidyl ether
IT Reinforced plastics
RL: TEM (Technical or engineered material use); USES (Uses)
(prepregs; pyridine condensate epoxy compound and cured epoxy resin product for)
IT Epoxy resins, preparation
RL: IMF (Industrial manufacture); PREP (Preparation)
(pyridine condensate epoxy compound and cured epoxy resin product)
IT Electric insulators
Printed circuit boards
(pyridine condensate epoxy compound and cured epoxy resin product for)
IT 815600-49-8P 815600-51-2P 815600-53-4P 815600-56-7P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and curing; pyridine condensate epoxy compound and cured epoxy resin product)
IT 815600-61-4P
RL: IMF (Industrial manufacture); PREP (Preparation)
(pyridine condensate epoxy compound and cured epoxy resin product)
IT 815600-57-8P 815600-58-9P 815600-59-0P
RL: IMF (Industrial manufacture); PRP (Properties); PREP (Preparation)
(pyridine condensate epoxy compound and cured epoxy resin product)
IT **815600-54-5P**
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(pyridine condensate epoxy compound and cured epoxy resin product)
IT 92-88-6, 4,4'-Biphenol 106-89-8, Epichlorohydrin, reactions 141-30-0, 3,6-Dichloropyridazine 626-16-4, 1,3-Bis(chloromethyl)benzene 2402-78-0, 2,6-Dichloropyridine 5424-21-5, 2,4-Dichloro-6-methylpyrimidine
RL: RCT (Reactant); RACT (Reactant or reagent)
(pyridine condensate epoxy compound and cured epoxy resin product)
IT 30062-98-7P 815600-50-1P 815600-52-3P **815600-55-6P** 815600-60-3P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(reaction with epichlorohydrin; pyridine condensate epoxy compound and cured epoxy resin product)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L13 2 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
IC ICM A61K031-4743

ICS C07D498-02
CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
TI Preparation of fused heterocycle kinase inhibitors for treatment of protein tyrosine kinase-related diseases
ST fused heterocycle prepn kinase inhibitor collagen induced arthritis; thienopyridine furopyridine pyrrolopyridine naphthyridine prepn COT MK2 kinase inhibitor; TNFa interleukin1 prodn inhibitor thienopyridine prepn
IT Growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(angiogenic factor; preparation of fused heterocycles as inhibitors of angiogenic receptor tyrosine kinases)
IT Growth inhibitors, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(angiogenic growth-inhibiting factor; preparation of fused heterocycles as inhibitors of angiogenic receptor tyrosine kinases)
IT Angiogenesis
(neovascularization; preparation of fused heterocycles as inhibitors of angiogenic receptor tyrosine kinases)
IT Interleukin 1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of fused heterocycles as inhibitors of IL-1 production resulting from LPS stimulation)
IT Interleukin 1β
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of fused heterocycles as inhibitors of IL-1β production resulting from LPS stimulation)
IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of fused heterocycles as inhibitors of TNF-α production resulting from LPS stimulation)
IT Arthritis
(preparation of fused heterocycles as inhibitors of collagen induced arthritis)
IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of fused heterocycles as inhibitors of cytokines production resulting from LPS stimulation)
IT Lipopolysaccharides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of fused heterocycles as inhibitors of pErk signaling resulting from LPS stimulation)
IT Human
(preparation of fused heterocycles as kinase inhibitors)
IT 98546-51-1P, 4-(Methylsulfanyl)phenylboronic acid 145325-40-2P, 4-Bromothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 251992-93-5P, 4-Phenylsulfanylthieno[2,3-c]pyridine-2-carboxamide 251993-33-6P, 4-(4-Iodophenoxy)thieno[2,3-c]pyridine-2-carboxamide 251993-41-6P, 4-Bromothieno[2,3-c]pyridine-2-carboxamide 251995-92-3P, 4-(3-Aminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870234-99-4P, 4-(4-Iodophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid 870235-00-0P, 4-Bromothieno[2,3-c]pyridine-2-carbonitrile 870235-01-1P, 4-Bromo-2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridine 870235-02-2P, 4-(4-Bromophenylamino)thieno[2,3-c]pyridine-2-carboxamide 870235-12-4P, [4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]amine 870235-15-7P, 4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxylic acid 870235-18-0P, 4-[[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]carbonyl]piperazine-1-carboxylic acid tert-butyl ester 870235-19-1P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870235-20-4P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid ditrifluoroacetate 870235-24-8P, 4-(Biphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870235-28-2P, 4-(3-Formylphenyl)thieno[2,3-

c]pyridine-2-carboxamide 870235-32-8P, 4-Bromo-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-34-0P, 4-[(Biphenyl-4-yl)amino]-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-41-9P 870235-43-1P, 4-[4-(2-Chloroacetylamino)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870235-44-2P, 4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870235-45-3P, 4-Fluorothieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870235-48-6P, 4-[(Biphenyl-4-yl)amino]-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid 870235-49-7P, 4-[(Biphenyl-4-yl)oxy]-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-51-1P, 4-(3-Chlorophenyl)thieno[2,3-c]pyridine-2-carboxylic acid 870235-52-2P 870235-55-5P, 4-(4-tert-Butylphenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870235-76-0P, 4-(4-Iodophenoxy)thieno[2,3-c]pyridine-2-carbonitrile 870235-77-1P, 4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carbonitrile 870235-78-2P, 4-[(Biphenyl-4-yl)amino]-7-chlorothieno[2,3-c]pyridine-2-carboxamide 870235-80-6P, 4-[3-[3-(m-Tolyl)ureido]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870235-82-8P, 4-(Biphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870235-83-9P, 4-(Biphenyl-3-yl)thieno[2,3-c]pyridine-2-carbonitrile 870236-18-3P, 4-(1H-Pyrazol-4-yl)thieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870236-27-4P, 4-[(Biphenyl-4-yl)amino]-7-cyanothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870236-42-3P, 4-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]piperidine-1-carboxylic acid tert-butyl ester 870236-44-5P, (R)-3-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]pyrrolidine-1-carboxylic acid tert-butyl ester 870237-40-4P, 4-(4-Aminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-79-9P, [3-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]amine 870238-30-5P, 4-[(4'-Chlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxylic acid 870238-31-6P, 4-(Biphenyl-3-yl)pyrrolo[2,3-c]pyridine-2-carboxylic acid 870238-39-4P, 4-Bromo-7-chlorothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870238-48-5P, 7-Amino-4-bromothieno[2,3-c]pyridine-2-carboxamide 870238-49-6P, 7-Amino-4-(3-chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-64-5P, 4'-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]biphenyl-4-carboxylic acid 870238-82-7P, 4-[(Piperidin-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870240-02-1P, [4-[(4'-Chlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]carbamic acid tert-butyl ester 870240-10-1P, 4-(4-Bromophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid (2-tert-butoxyethoxy)amide 870240-11-2P, 4-[[4-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)phenyl]carbamoyl]piperidine-1-carboxylic acid tert-butyl ester 870240-40-7P, 3-[[[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]carbonyl]amino]propionic acid tert-butyl ester 870241-11-5P, 4-(4-Iodophenoxy)thieno[2,3-c]pyridine 870241-33-1P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxaldehyde 870241-34-2P, (1S,4S)-4-(2,5-Diazabicyclo[2.2.1]hept-2-yl)thieno[2,3-c]pyridine-2-carboxamide 870241-35-3P, 4-((1S,4S)-5-Benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)thieno[2,3-c]pyridine-2-carboxamide 870241-36-4P, 4-((3R)-Pyrrolidin-3-ylamino)thieno[2,3-c]pyridine-2-carboxamide 870241-37-5P, 4-[((R)-1-Benzylpyrrolidin-3-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870241-71-7P, 4-(Biphenyl-3-yl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid methyl ester 870241-74-0P, 4-(Biphenyl-3-yl)-1H-pyrrolo[2,3-c]pyridine-2-carboxamide 870242-92-5P, 4-Bromopyrrolo[2,3-c]pyridine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 870242-94-7P, [7-(Biphenyl-3-yl)-3-bromothieno[2,3-c]pyridin-4-yl]amine 870242-95-8P, [7-(Biphenyl-3-yl)-3-cyanothieno[2,3-c]pyridin-4-yl]amine 870243-07-5P, 4-Chlorofuro[2,3-c]pyridine-2-carboxylic acid ethyl ester 870243-08-6P 870243-10-0P, N-Hydroxy-4-(4-iodophenoxy)thieno[2,3-c]pyridine-2-carboximidamide 870243-13-3P, 4-[(Biphenyl-4-yl)oxy]-N-hydroxythieno[2,3-c]pyridine-2-carboximidamide 870243-27-9P, 4-Bromo-6-oxothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870243-29-1P, 4-[(Biphenyl-4-yl)amino]-7-chlorothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870243-31-5P, 7-Amino-4-[(biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870243-37-1P, [[4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridin-

2-yl]methyl]amine 870243-51-9P, 7-(Biphenyl-3-yl)thieno[2,3-c]pyridin-4-amine 870243-64-4P, (2-Methoxycarbonylthieno[2,3-c]pyridin-4-yl)ammonium chloride 870243-70-2P, [2-(5-Amino-[1,2,4]oxadiazol-3-yl)thieno[2,3-c]pyridin-4-yl](biphenyl-4-yl)amine 870243-75-7P 870243-84-8P, 3-[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]-3-oxopropionitrile 870243-89-3P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic hydrazide 870244-11-4P, N'-(Biphenyl-4-yl)thieno[2,3-c]pyridine-2,4-diamine dihydrochloride 870244-24-9P, 4-(Biphenyl-3-yl)-5-chlorothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870244-27-2P, 5-Chlorothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870244-28-3P, 4-Bromo-3-methylthieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870244-30-7P, 4-(4-Bromophenylamino)-3-methylthieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870244-37-4P, 4-(Biphenyl-3-yl)-1-(2-methoxycarbonylethyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid methyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

IT 2646-90-4P, 2,5-Difluorobenzaldehyde 5470-96-2P, 2-Quinolinecarboxaldehyde 5779-95-3P, 3,5-Dimethylbenzaldehyde 5973-71-7P, 3,4-Dimethylbenzaldehyde 10203-08-4P, 3,5-Dichlorobenzaldehyde 22078-59-7P, 5-(3-Chlorophenyl)furan-2-carboxaldehyde 63019-98-7P, (3-Methylbiphenyl-4-yl)amine 251993-28-9P, 4-Phenoxythieno[2,3-c]pyridine-2-carboxamide 251993-43-8P, 4-(4-Trifluoromethylphenyl)thieno[2,3-c]pyridine-2-carboxamide 251993-45-0P, 4-Phenylthieno[2,3-c]pyridine-2-carboxamide 251995-86-5P 251995-88-7P, 4-(4-Chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide 251995-89-8P, 4-(3-Trifluoromethylphenyl)thieno[2,3-c]pyridine-2-carboxamide 251995-94-5P, 4-(3,5-Dichlorophenyl)thieno[2,3-c]pyridine-2-carboxamide 251996-53-9P 870235-03-3P, 4-(4-Bromophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870235-05-5P, (5-Phenylpyridin-2-yl)[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870235-06-6P 870235-07-7P, 4-(Phenethynyl)thieno[2,3-c]pyridine-2-carboxamide 870235-08-8P, 4-[4-[(Phenylsulfonyl)amino]phenoxy]thieno[2,3-c]pyridine-2-carboxamide 870235-09-9P, 4-[3-[(Cyclopropylmethyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870235-10-2P, 4-[4-(3-Phenylureido)phenoxy]thieno[2,3-c]pyridine-2-carboxamide 870235-11-3P, N-[4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-trifluoromethylbenzamide 870235-13-5P, [3-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)phenyl]carbamic acid isopropyl ester 870235-16-8P, [4-(4-Iodophenoxy)thieno[2,3-c]pyridin-2-yl]amine 870235-17-9P, 4-[3-[[(Pyridin-4-yl)carbonyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870235-21-5P, 4-[(2,6-Dimethylbiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870235-22-6P, 4-(3-Isopropoxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870235-25-9P, 4-[(Biphenyl-4-yl)oxy]-2-phenylthieno[2,3-c]pyridine 870235-27-1P, 4-[3-[[[2-(Piperidin-1-yl)ethyl]amino]methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870235-29-3P, 4-[[4-(Thiophen-3-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxylic acid 870235-33-9P, 4-[(Biphenyl-4-yl)amino]-1H-pyrrolo[2,3-c]pyridine-2-carboxamide 870235-38-4P, [4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]acetic acid 870235-40-8P, 1-[4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]pyrrolidine-2,5-dione 870235-42-0P, 4-[4-[[2-(Pyrazol-1-yl)acetyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870235-46-4P, 4-Fluorothieno[2,3-c]pyridine-2-carboxylic acid 870235-50-0P, 4-[(Biphenyl-4-yl)oxy]-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid 870235-53-3P, 7-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870235-57-7P, 3'-(7-Amino-2-carbamoylthieno[2,3-c]pyridin-4-yl)biphenyl-4-carboxylic acid 870235-59-9P, 7-Amino-4-(3',4'-dimethoxybiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870235-61-3P, 7-Amino-4-(4'-carbamoylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-

carboxylic acid 870235-63-5P, 7-Amino-4-(4'-methoxybiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870235-65-7P, 7-Amino-4-[3-(benzo[b]thiophen-3-yl)phenyl]thieno[2,3-c]pyridine-2-carboxylic acid 870235-67-9P, 7-Amino-4-(4'-ethylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870235-69-1P, 7-Amino-4-[3-(pyridin-4-yl)phenyl]thieno[2,3-c]pyridine-2-carboxylic acid 870235-71-5P, 7-Amino-4-(3'-methylsulfonylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870235-73-7P, 4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870235-75-9P, 5-[(Biphenyl-3-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870235-79-3P, 4-[(Biphenyl-4-yl)amino]-7-chlorothieno[2,3-c]pyridine-2-carbonitrile 870235-81-7P, 1-[3-(2-Cyanothieno[2,3-c]pyridin-4-yl)phenyl]-3-(m-tolyl)urea 870235-85-1P, (3,5-Dimethylbiphenyl-4-yl)[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870235-87-3P, (3-Fluorobiphenyl-4-yl)[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870235-89-5P, (3-Chlorobiphenyl-4-yl)[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870235-91-9P, [2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl](3-trifluoromethylbiphenyl-4-yl)amine 870235-93-1P, [2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl](2-trifluoromethylbiphenyl-4-yl)amine 870235-95-3P, (3-Methylbiphenyl-4-yl)[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870235-96-4P, 4-(Biphenyl-3-yl)[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870235-98-6P, 4-[(2-Chlorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-00-3P, 4-[(3,5-Difluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-01-4P, 4-[(3,5-Difluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-02-5P, 4-[(3,5-Dimethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-03-6P, 4-[(3-Fluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-04-7P, 4-[(3-Fluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-05-8P, 4-[(3-Chlorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-06-9P, 4-[(3-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-07-0P, 4-[(3-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-08-1P, 4-[(2-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-09-2P, 4-[(2-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-10-5P, 4-[(3-Methoxybiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-12-7P, 4-[(3-Methoxybiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-14-9P, 4-(3-Chlorophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870236-15-0P, 4-[(2-Chlorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-16-1P, 4-[(3-Methylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-17-2P, 4-[(3-Methylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-19-4P, 4-(1H-Pyrazol-4-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870236-21-8P, 4-(4-Hydroxyphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-23-0P, 4-(4-Aminophenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-25-2P, 4-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)benzoic acid 870236-26-3P, 4-(4-Hydroxyphenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870236-28-5P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2,7-dicarboxylic acid 870236-29-6P, 4-(4-Aminophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870236-31-0P, 4-(Cyclohexylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-33-2P, 4-(4-Phenylcyclohexylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-35-4P, 4-[(1-Benzylpiperidin-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-36-5P, 4-[(1-Benzylpiperidin-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-38-7P, (1R,5R)-6-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylic acid benzyl ester 870236-40-1P, 4-[(4'-Formylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-46-7P, 4-((3AS,6aR)-5-Benzylhexahydropyrrolo[3,4-c]pyrrol-2-yl)thieno[2,3-c]pyridine-2-carboxamide 870236-48-9P, 4-(2-Benzyloctahydropyrrolo[3,4-c]pyridin-5-yl)thieno[2,3-c]pyridine-2-

carboxamide 870236-50-3P, 4-(2-Benzyl-1-oxo-2,8-diazaspiro[4.5]decan-8-yl)thieno[2,3-c]pyridine-2-carboxamide 870236-52-5P, 4-(1-Oxo-2-phenyl-2,8-diazaspiro[4.5]decan-8-yl)thieno[2,3-c]pyridine-2-carboxamide 870236-54-7P, (1R,4S)-5-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 870236-55-8P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-56-9P, 4-(3-Phenoxyphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-57-0P, 4-(4-Phenoxyphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-58-1P, 4-[(Naphthalen-2-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-60-5P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870236-61-6P, 4-(4-Bromophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870236-62-7P, 4-[(Naphthalen-2-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-63-8P, 4-[[4-(Pyridin-4-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-64-9P, 4-[(4'-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-65-0P, 4-[(4'-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870236-66-1P, 4-[[4-(1H-Pyrazol-4-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-67-2P, 4-[(Phenyl)[2-(pyrrolidin-1-yl)ethyl]amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-68-3P, 4-Phenylaminothieno[2,3-c]pyridine-2-carboxamide 870236-69-4P, (2-Methylbiphenyl-4-yl)[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870236-70-7P, 4-(2-Methylbiphenyl-4-ylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-72-9P 870236-74-1P, 4-[(2-Methyl-5-phenyl-2H-pyrazol-3-yl)amino]thieno[2,3-c]pyridine-2-carboxamide acetate 870236-75-2P, (4-tert-Butylphenyl)[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870236-76-3P, 4-[[4-(1H-Benzimidazol-2-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-77-4P, 4-[(4'-Cyanobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-78-5P, N-(2-Aminocarbonylthieno[2,3-c]pyridin-4-yl)-4-[[4-(morpholin-4-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870236-79-6P, 4-[[4-(Morpholin-4-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870236-80-9P, N-(2-Aminocarbonylthieno[2,3-c]pyridin-4-yl)-4-[[4-(cyclohexyl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870236-81-0P, 4-(4-Cyclohexylphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-82-1P, 4-[(5-Phenylpyridin-2-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-83-2P, 4-[[4'-[[2-(Piperidin-4-yl)ethyl]carbamoyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870236-84-3P, 4-(4-tert-Butylphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-85-4P, 8-[(Biphenyl-4-yl)amino][1,6]naphthyridine-2-carboxylic acid 870236-86-5P, 4-(4-tert-Butylphenylamino)thieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870236-87-6P, 4-(4-Nitrophenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-88-7P, 4-(3,4-Dichlorophenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-89-8P, 4-[(4-Nitro-3-trifluoromethylphenyl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-90-1P, 4-[(2,3-Dihydrobenzo[1,4]dioxin-6-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-91-2P, 4-[(4-Trifluoromethylphenyl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-92-3P, 4-[(4-Fluorophenyl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-93-4P, 4-[(4-Chlorophenyl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-94-5P, 4-(4-Ethoxyphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-95-6P, 4-(p-Tolylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-96-7P, 4-[(Indan-5-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-97-8P, 4-(4-Ethylphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-98-9P, 4-(4-Bromo-2-fluorophenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-99-0P, 4-(3,4-Dichlorophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870237-00-6P, 4-[(4-Nitro-3-trifluoromethylphenyl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870237-01-7P, 4-[(4-Trifluoromethylphenyl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870237-02-8P, 4-(4-Cyanophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870237-03-9P, 4-(4-Fluorophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870237-04-0P,

4-(4-Chlorophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870237-05-1P, 4-[(4-Dimethylaminophenyl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870237-06-2P, 4-(4-Methoxyphenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870237-07-3P, 4-(4-Ethoxyphenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870237-08-4P, 4-(p-Tolylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870237-09-5P, 4-[(Indan-5-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870237-10-8P, 4-(4-Ethylphenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870237-11-9P, 4-(4-Bromo-2-fluorophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870237-12-0P, 4-[(2-Methyl-1H-indol-5-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870237-13-1P, 4-[(1H-Indol-5-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870237-14-2P, 4-[(Benzodioxol-5-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870237-15-3P, 4-[[4-(Morpholin-4-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxylic acid 870237-16-4P, 4-(Acetylphenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870237-17-5P, 4-[(4-Trifluoromethoxyphenyl)amino]thieno[2,3-c]pyridine-2-carboxamide 870237-18-6P, 4-[(2-Methylbenzothiazol-5-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870237-19-7P, 4-[[3-[(Dimethylamino)methyl]-4-hydroxyphenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870237-20-0P, 4-(4-Bromo-3-fluorophenylamino)thieno[2,3-c]pyridine-2-carboxamide 870237-21-1P, 4-[(1-Acetyl-2,3-dihydro-1H-indol-6-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870237-22-2P, 4-(4-Vinylphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870237-23-3P, 4-[4-(Cyanomethyl)phenylamino]thieno[2,3-c]pyridine-2-carboxamide 870237-24-4P, 4-(4-Propoxyphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870237-25-5P, 4-[(4-Phenylcarbamoylphenyl)amino]thieno[2,3-c]pyridine-2-carboxamide 870237-26-6P, 4-[[4-(Difluoromethoxy)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870237-27-7P, 4-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]benzoic acid ethyl ester 870237-28-8P, 4-[[4-(Piperidin-1-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870237-29-9P, 4-[(4-Chloro-3-trifluoromethylphenyl)amino]thieno[2,3-c]pyridine-2-carboxamide 870237-30-2P, 4-[[4-[Cyano(phenyl)methyl]phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870237-31-3P, 4-[(3'-Cyanobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870237-32-4P, 4-(5-Benzylhexahydropyrrolo[3,4-c]pyrrol-2-yl)thieno[2,3-c]pyridine-2-carboxamide 870237-34-6P, 4-((3aS,7aR)-2-Benzyloctahydropyrrolo[3,4-c]pyridin-5-yl)thieno[2,3-c]pyridine-2-carboxamide 870237-36-8P, 4-[(8-Benzyl-8-azabicyclo[3.2.1]oct-3-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870237-37-9P, 4-[(1-Phenylpiperidin-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870237-38-0P, 4-(Naphthalen-1-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870237-39-1P, 4-([2,2']Bithiophenyl-5-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870237-41-5P, 4-(Pyridin-4-yl)thieno[2,3-c]pyridine-2-carboxamide 870237-42-6P, 4-(2-Methylphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-43-7P, 4-(4-Methylphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-44-8P, 4-(4-Hydroxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-45-9P, 4-(3-Hydroxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-46-0P, 4-(2,5-Dimethylphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-47-1P, 4-(4-Hydroxymethylphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-48-2P, 4-(3-Hydroxymethylphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-49-3P, 4-(4-Methoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-50-6P, 4-(2-Hydroxymethylphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-51-7P, 4-(5-Fluoro-2-methoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-52-8P, 4-(2-Fluoro-3-methoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-53-9P, 4-(Naphthalen-1-yl)thieno[2,3-c]pyridine-2-carboxamide 870237-54-0P, 4-(Benzo[b]thiophen-2-yl)thieno[2,3-c]pyridine-2-carboxamide 870237-55-1P, 4-(3,4-Dimethoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-56-2P 870237-57-3P, 4-(Biphenyl-2-yl)thieno[2,3-c]pyridine-2-carboxamide 870237-58-4P, 4-(2-Chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-59-5P, 4-(2,3-Difluorophenyl)thieno[2,3-c]pyridine-2-carboxamide

870237-60-8P, 4-(Benzofuran-2-yl)thieno[2,3-c]pyridine-2-carboxamide
870237-61-9P, 4-(4-Acetylphenyl)thieno[2,3-c]pyridine-2-carboxamide
870237-62-0P, 4-(2,3-Dihydrobenzofuran-5-yl)thieno[2,3-c]pyridine-2-carboxamide 870237-63-1P, 4-(3-Isopropylphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-64-2P, 4-(4-Dimethylaminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-65-3P, 4-(Benzodioxol-5-yl)thieno[2,3-c]pyridine-2-carboxamide 870237-66-4P, 4-(3-Ethoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-67-5P, 4-(3-Nitrophenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-68-6P, 4-(4-Methylsulfonylphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-69-7P, 4-(3-Trifluoromethoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-70-0P, 4-(4-Trifluoromethoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-71-1P, 4-(2-Trifluoromethoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-72-2P, 4-(2-Phenoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-73-3P, 4-(2-Fluorobiphenyl-4-yl)thieno[2,3-c]pyridine-2-carboxamide 870237-74-4P, 4-[4-[4-(Tetrahydropyran-2-yl)oxy]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870237-75-5P, 4-(4-Benzyloxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-76-6P, 4-(2-Benzyloxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-77-7P, 4-(4-Acetylaminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-78-8P, 4-[1-(Phenylsulfonyl)-1H-indol-3-yl]thieno[2,3-c]pyridine-2-carboxamide 870237-80-2P, 2-(1H-Tetrazol-5-yl)-4-(3-trifluoromethylphenyl)thieno[2,3-c]pyridine 870237-81-3P, 4-(3,5-Dichlorophenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870237-82-4P, 4-(3,4-Dimethoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870237-83-5P, 4-(5-Fluoro-2-methoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870237-84-6P, 2-(1H-Tetrazol-5-yl)-4-(4-trifluoromethoxyphenyl)thieno[2,3-c]pyridine 870237-85-7P, [4-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]methanol 870237-86-8P, N-[4-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]acetamide 870237-87-9P, 4-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenol 870237-88-0P, 4-(3-Isopropoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870237-89-1P, 3-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenol 870237-90-4P, 4-(2-Benzyloxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870237-91-5P, 4-(Pyridin-4-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870237-92-6P, 4-[1-(Phenylsulfonyl)-1H-indol-3-yl]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870237-93-7P, 4-(3,4-Dihydro-2H-benzo[b]dioxepin-7-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870237-94-8P, 4-(Biphenyl-4-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870237-95-9P, 4-(2-Fluorobiphenyl-4-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870237-96-0P, 1-[4-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]ethanone 870237-97-1P, 7-Amino-4-(4'-methoxybiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870237-98-2P, 2-(1H-Tetrazol-5-yl)-4-(2-methylphenyl)thieno[2,3-c]pyridine 870237-99-3P, 4-(2-Chlorophenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-00-9P, 4-(Benzodioxol-5-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-01-0P, 4-(4-Methoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-02-1P, 2-(1H-Tetrazol-5-yl)-4-(2-trifluoromethoxyphenyl)thieno[2,3-c]pyridine 870238-03-2P, 4-(2,3-Dihydrobenzofuran-5-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

IT 870238-04-3P, 2-(1H-Tetrazol-5-yl)-4-(4-methylphenyl)thieno[2,3-c]pyridine 870238-05-4P, [3-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]methanol 870238-06-5P, 2-(1H-Tetrazol-5-yl)-4-(3-trifluoromethoxyphenyl)thieno[2,3-c]pyridine 870238-07-6P, 4-(Biphenyl-2-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-08-7P, 4-(2-Phenoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-09-8P, 4-(3-Nitrophenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-10-1P, 4-[2-(1H-Tetrazol-5-yl)thieno[2,3-

c]pyridin-4-yl]quinoline 870238-11-2P, 4-(4-Chlorophenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-12-3P, 4-(3-Ethoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-13-4P, 4-(4-Methylsulfanylphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-14-5P, 4-(4-Benzyloxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-15-6P, 4-(2-Fluoro-3-methoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-16-7P, 4-[4-[(Tetrahydropyran-2-yl)oxy]phenyl]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-17-8P, 4-Phenyl-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-18-9P, 4-(Biphenyl-4-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-19-0P 870238-21-4P, 4-(4-Amino-3-chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-22-5P, 4-(3-Fluorobiphenyl-4-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-23-6P, 4-(Thiophen-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-24-7P, 4-(4-Formylphenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-25-8P, 3-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)benzoic acid 870238-26-9P, 4-(3-Cyanophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-27-0P, 4-(Naphthalen-2-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-28-1P, 4-(4-Phenoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-29-2P, 4-(3-Benzyloxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-32-7P, 4-(3-Chloro-4-ethoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-33-8P, 4-(5-Chloro-2-methylphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-34-9P, 4-(5-Chloro-2-ethoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-35-0P, 4-(3-Chloro-4-methylphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-37-2P, 4-Chloro-2-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]benzaldehyde 870238-38-3P, (5-Methylbenzoxazol-2-yl)[4-[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]amine 870238-42-9P, 4-Phenyl-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid 870238-43-0P, 4-(1-Methyl-1H-indol-5-yl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid 870238-44-1P, 4-(4'-Methoxybiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870238-46-3P, 4-[[4-(Benzo[b]thiophen-3-yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-47-4P, 2-(1H-Tetrazol-5-yl)-4-[(2',3',4'-trimethoxybiphenyl-4-yl)oxy]thieno[2,3-c]pyridine 870238-50-9P, 7-Amino-4-(4'-methylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-51-0P, 7-Amino-4-(3'-cyanobiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-52-1P, 7-Amino-4-(2'-cyanobiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-53-2P, 7-Amino-4-(2'-methylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-54-3P, 4-[(4'-Nitrobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-55-4P, 4-[(4'-Acetylaminobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-56-5P, 4-[(4'-Acetylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-57-6P, 4-[(4'-Dimethylaminobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-58-7P, 4-[(4'-Aminobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-59-8P, 4-[(4'-Methylsulfonylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-60-1P, 4-[(4'-Fluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-61-2P, 4-[(4'-Methoxymethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-62-3P, 4-[(4'-Cyano-3'-methylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-63-4P, 4-[(4'-Carbamoylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-66-7P, 4-[(4'-Ethynylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-68-9P, 4-[(4'-Cyano-3'-fluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-69-0P, 7-Amino-4-(3-aminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-71-4P, 7-Amino-4-[4-[(phenylacetyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-72-5P, 7-Amino-4-[4-(3-phenylureido)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-73-6P, 7-Amino-4-(3-benzoylaminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-74-7P, 7-Amino-4-(4-aminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-75-8P, 7-Amino-4-[4-[(benzoxazol-2-yl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-76-9P, 4-[3-[(3-Tolylsulfonyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide

870238-77-0P, 4-[3-[[(2-Chloro-4-trifluoromethylphenyl)sulfonyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-78-1P, 4-[3-[(Thien-2-ylsulfonyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-79-2P, 3-Methyl-N-[4-[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]benzenesulfonamide 870238-80-5P, 4-[4-[(3-Tolylsulfonyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-81-6P, 4-[4-[(Phenylsulfonyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-83-8P, 4-[[1-(Phenylsulfonyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870238-85-0P, N-[4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]methanesulfonamide 870238-86-1P 870238-87-2P, [2-[[3-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)phenyl]amino]ethyl]carbamic acid tert-butyl ester 870238-88-3P, 4-[3-[(Pyridin-4-ylmethyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-89-4P, 4-(3-Benzylaminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-90-7P, (Cyclopropylmethyl)[3-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]amine 870238-91-8P, (Cyclopropylmethyl)[4-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]amine 870238-92-9P, [(Pyridin-2-yl)methyl][3-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]amine 870238-93-0P, [(Pyridin-3-yl)methyl][3-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]amine 870238-94-1P, 4-(3-Phenethylaminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-95-2P, 4-[3-(3-Phenylpropylamino)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-96-3P, 4-[3-[(2-Methoxybenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-97-4P, 4-[3-[(3-Methoxybenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-98-5P, 4-[3-[(4-Methoxybenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-99-6P, 4-[3-[(2-Chlorobenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-00-2P, 4-[3-[(3-Chlorobenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-01-3P, 4-[3-[(4-Chlorobenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-02-4P, 4-[3-[(2-Trifluoromethylbenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-03-5P, 4-[3-[(3-Trifluoromethylbenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-04-6P, 4-[3-[(4-Trifluoromethylbenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-05-7P, 4-[3-[(2,4-Dimethoxybenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-06-8P, 4-[3-[(2,4-Dichlorobenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-07-9P, 4-[3-[[(2,3-Dihydrobenzo[1,4]dioxin-6-yl)methyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-08-0P, 4-[3-(3-Cyclopentylureido)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-09-1P, 4-[3-[3-(2-Fluoro-5-trifluoromethylphenyl)ureido]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-10-4P, 1-[3-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-(m-tolyl)urea 870239-11-5P, 1-[4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-(m-tolyl)urea 870239-12-6P, 1-Phenyl-3-[4-[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]urea 870239-13-7P, 1-[4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-(o-tolyl)urea 870239-14-8P, 1-[4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-(p-tolyl)urea 870239-15-9P, 1-[4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-(2-trifluoromethylphenyl)urea 870239-16-0P, 1-[4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 870239-17-1P, 1-[4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-(4-trifluoromethylphenyl)urea 870239-18-2P, 1-(2,5-Dichlorophenyl)-3-[4-[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]urea 870239-19-3P, 1-(3,5-Dichlorophenyl)-3-[4-[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]urea 870239-20-6P, 1-(2,6-Dichlorophenyl)-3-[4-[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]urea 870239-21-7P, 4-[4-(3-Phenylureido)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-22-8P, 4-[4-[3-(3-Trifluoromethylphenyl)ureido]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-23-9P, 4-[4-(3-Isopropylureido)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-25-1P, 4-[[1-[(Phenylthio)carbamoyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-26-2P,

4-[[1-[(3,4-Dimethoxyphenyl)carbamoyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-27-3P, 1-[4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]-3-ethylurea 870239-28-4P, 1-Ethyl-3-[4-(4'-methoxybiphenyl-3-yl)thieno[2,3-c]pyridin-2-yl]urea 870239-29-5P, 4-[3-(2-Fluoro-4-trifluoromethylbenzoylamino)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-30-8P, 4-[3-(3-Trifluoromethylbenzoylamino)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-31-9P, 4-[3-[[(Thien-2-yl)carbonyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-32-0P, 4-[4-(3-Trifluoromethylbenzoylamino)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-33-1P, 4-(4-Benzoylaminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870239-34-2P, 4-(4-Isobutanoylaminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870239-35-3P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid (3-hydroxypropyl)amide 870239-38-6P 870239-39-7P, 4-[[4-[(Piperidin-4-yl)carbamoyl]phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-40-0P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid dimethylamide 870239-41-1P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid methylamide 870239-42-2P, 4-[[4-(4-Cyanophenylcarbamoyl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-43-3P, 4-[[4-[(3,4-Dimethoxyphenyl)carbamoyl]phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-44-4P, 4-[[4-(3-Cyanophenylcarbamoyl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-45-5P, 4-[[4-(4-Sulfamoylphenylcarbamoyl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-46-6P, 4-[[4-(Isopropylcarbamoyl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-47-7P, 4-[[4-(Benzylcarbamoyl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-48-8P, 3-[4-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]benzoylamino]azetidine-1-carboxylic acid tert-butyl ester 870239-49-9P, 4-[[4-(Cyclohexylcarbamoyl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-51-3P 870239-52-4P, 4-[[4-[(2-Methylsulfanylethyl)carbamoyl]phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-53-5P, 4-[[4-[Methyl(2-methylsulfanylethyl)carbamoyl]phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-55-7P, 4-[(1-Benzoylpiperidin-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870239-56-8P, 4-[[1-(Phenylacetyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-57-9P, 4-[[1-(3-Phenylpropionyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-58-0P, 4-[[1-(3-Cyanobenzoyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-59-1P, 4-[[1-(4-Methoxybenzoyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-60-4P, 4-[[1-(2-Methoxybenzoyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-61-5P, 4-[[1-[(Pyridin-2-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-62-6P, 4-[[1-[(Pyridin-3-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-63-7P, 4-[[1-[(Pyridin-4-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-64-8P, 4-[[1-(2-Dimethylaminoacetyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-65-9P, 4-[[1-[(Isoxazol-5-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-66-0P, 4-[[1-[(Benzodioxol-5-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-67-1P, 4-[[1-[(Thien-2-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-68-2P, 4-[[1-[2-(2-Methoxyethoxy)acetyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-69-3P, 4-[[1-[(3,5-Dimethylisoxazol-4-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-70-6P, 4-[4-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]piperidin-1-yl]-4-oxobutanoic acid methyl ester 870239-71-7P, 4-[[1-[(1-Acetylpiperidin-4-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-72-8P, 4-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]piperidine-1-carboxylic acid phenyl ester 870239-73-9P, 4-[[1-(Trifluoromethylacetyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-74-0P, N-[4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]acetamide

870239-75-1P 870239-76-2P, N-[4-([2,2']Bithiophenyl-5-yl)-3-(2,2,2-trifluoroacetyl)thieno[2,3-c]pyridin-2-yl]-2,2,2-trifluoroacetamide 870239-78-4P, N-[4-(4'-Methoxybiphenyl-3-yl)thieno[2,3-c]pyridin-2-yl]acetamide 870239-79-5P, 2,2,2-Trifluoro-N-[4-(4'-methoxybiphenyl-3-yl)thieno[2,3-c]pyridin-2-yl]acetamide 870239-80-8P, 2-Methoxy-N-[4-(4'-methoxybiphenyl-3-yl)thieno[2,3-c]pyridin-2-yl]acetamide 870239-81-9P, Acetic acid [[4-([2,2']bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]carbamoyl]methyl ester 870239-82-0P, N-[4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]oxalamic acid ethyl ester 870239-83-1P, Isoxazole-5-carboxylic acid N-[4-([2,2']bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]amide 870239-84-2P, N-[4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]-2-dimethylaminoacetamide 870239-85-3P, 4-[[4'-(Butylcarbamoyl)biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-86-4P, 4-[(4'-Methylcarbamoylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870239-87-5P, 4-[[4'-(Dimethylcarbamoyl)biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-88-6P, 4-[[4'-(Isopropylcarbamoyl)biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-89-7P, 4-[[4'-(2-Hydroxyethylcarbamoyl)biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-90-0P, 4-[[4'-(3-Hydroxypropylcarbamoyl)biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-91-1P, 4-[[4'-[(2-Ethylaminoethyl)carbamoyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-92-2P, 4-[[4'-[(2-Diethylaminoethyl)carbamoyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-93-3P, 4-[[4'-[[2-(Morpholin-4-yl)ethyl]carbamoyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-94-4P, 4-[[4'-[(Piperazin-1-yl)carbonyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-95-5P, 4-[[4'-[(4-Methylpiperazin-1-yl)carbonyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-96-6P, 4-[[4'-[(Morpholin-4-yl)carbonyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-97-7P, 4-[[4'-(2-Methoxyethylcarbamoyl)biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-98-8P, 4-[[4'-[[3-(Pyrrolidin-1-yl)propyl]carbamoyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-99-9P, 4-[[4'-[[2-(Pyrrolidin-1-yl)ethyl]carbamoyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870240-00-9P, [4-(4-tert-Butylphenylamino)thieno[2,3-c]pyridin-2-yl]carbamic acid tert-butyl ester 870240-01-0P, [4-(3-Chlorophenyl)thieno[2,3-c]pyridin-2-yl]carbamic acid tert-butyl ester 870240-03-2P, [4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]carbamic acid tert-butyl ester 870240-05-4P, N-[4-(4-tert-Butylphenylamino)thieno[2,3-c]pyridin-2-yl]-2,2,2-trifluoroacetamide 870240-06-5P, [4-[(4'-Chlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]amine 870240-07-6P, N-[4-[(4'-Chlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]acetamide 870240-08-7P, [3-[4-[(4'-Chlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]ureido]acetic acid ethyl ester 870240-09-8P, 4-(4-Bromophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid (2-hydroxyethoxy)amide 870240-12-3P, 4-[4-[[(Piperidin-4-yl)carbonyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870240-15-6P, 7-Amino-4-(3'-trifluoromethylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid trifluoroacetate 870240-17-8P, 7-Amino-4-(4'-cyanobiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid acetate 870240-19-0P 870240-20-3P, 4-[4-(2-Phenylaminoacetylamino)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870240-21-4P, 4-[[3-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)phenyl]carbamoyl]piperidine-1-carboxylic acid tert-butyl ester 870240-22-5P, 4-[3-[(1-Methylcyclopropylcarbonyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870240-23-6P, 4-[4-(Isopropylcarbamoyl)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870240-24-7P 870240-25-8P, 4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxylic acid N-(benzyloxy)amide 870240-26-9P 870240-27-0P, [4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]piperidin-1-ylmethanone

870240-28-1P, [4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl](4-methylpiperazin-1-yl)methanone 870240-29-2P, [4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl](morpholin-4-yl)methanone 870240-30-5P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid N-(pyridin-4-yl)amide 870240-32-7P 870240-34-9P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [3-(morpholin-4-yl)propyl]amide diacetate 870240-35-0P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid propylamide 870240-36-1P, 4-[[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]carbonyl]piperazin-2-one 870240-37-2P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid (2-aminoethyl)amide 870240-38-3P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid (2-dimethylaminoethyl)amide 870240-41-8P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid allyloxyamide 870240-42-9P 870240-43-0P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid isobutoxyamide 870240-44-1P, (2S)-2-[[[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]carbonyl]amino]-3-tert-butoxypropionic acid tert-butyl ester 870240-45-2P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [(5-chloro-1,2,3-thiadiazol-4-yl)methoxy]amide 870240-46-3P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [(4-methylbenzyl)oxy]amide 870240-47-4P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [(2-chlorobenzyl)oxy]amide 870240-48-5P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [(3-chlorobenzyl)oxy]amide 870240-49-6P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [(2-methoxybenzyl)oxy]amide 870240-50-9P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [(3-methoxybenzyl)oxy]amide 870240-51-0P, 4-(4-Bromophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid methoxyamide 870240-53-2P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [(4-methoxybenzyl)oxy]amide 870240-54-3P, 4-[(Biphenyl-3-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-55-4P, 4-(3-Phenoxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-56-5P, 4-[(3-tert-Butylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-57-6P, 4-[(2-tert-Butylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-58-7P, 4-[(4-tert-Butylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-59-8P 870240-60-1P, 2-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]fluoren-9-one 870240-61-2P, 4-[[3-(Morpholin-4-yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-62-3P, 4-[(4-Cyclopentylphenyl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870240-63-4P, 4-[(4-Cyclopentylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-64-5P, 4-(4-Phenoxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-65-6P
, 4-(2-Isopropoxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-66-7P, 4-[(2-Cyclopentylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-67-8P, 4-(3-Isopropyl-5-methylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-68-9P, 4-(2-tert-Butyl-4-ethylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-69-0P, 4-[4-(1-Methyl-1-phenylethyl)phenoxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-70-3P 870240-71-4P, 5-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]isoquinoline 870240-72-5P, 4-[(5,6,7,8-Tetrahydronaphthalen-1-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

IT 870240-73-6P, 4-(4-Chloro-3-ethyl-5-methylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-74-7P, 4-[[4-(Indan-1-yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-75-8P,

4-(2-Ethyl-4,5-dimethylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-76-9P, 4-(3-Ethyl-5-methylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-77-0P, 4-(2-Benzyl-4-methylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-78-1P, 4-(2-Methyl-4-methylsulfanylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-79-2P, 4-[(5-tert-Butylbiphenyl-2-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-80-5P, [3-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]phenyl]acetic acid methyl ester 870240-81-6P, 4-[(2-Isopropylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-82-7P, 4-[(2-sec-Butylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-83-8P, 4-[(2,3-Dimethylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-84-9P, 4-[(2,4-Dimethylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-85-0P, 4-[(2,5-Dimethylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-86-1P, 4-[(2-Benzylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-87-2P, 4-[(2-Ethylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-88-3P, 4-(3-Cyanophenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-89-4P, 4-(3-Chlorophenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-90-7P, 4-(3-Methoxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-91-8P, 4-[(3-Isopropylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-92-9P, 4-[(3,4-Dimethylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-93-0P, 4-[(3,5-Dimethylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-94-1P, 4-(4-Chloro-2-methylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-95-2P, 4-(2,3-Dimethoxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-96-3P, 4-(3,5-Dimethoxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-97-4P, 4-(3,4-Dimethoxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-98-5P, 4-(4-tert-Butyl-2-methylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-99-6P, 4-(3-Benzyloxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-00-2P, 4-(2-Ethoxy-4-methylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-01-3P, 4-(2-Isopropyl-5-methylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-02-4P, 4-[(Naphthalen-1-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-03-5P, 4-(3-Ethoxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-04-6P, 4-(2-Methoxy-5-methylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-05-7P, 3-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]benzoic acid methyl ester 870241-06-8P, 4-[(2,6-Dimethylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-07-9P, 4-[(3-Ethylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-08-0P, 2-(1H-Tetrazol-5-yl)-4-(m-tolyloxy)thieno[2,3-c]pyridine 870241-09-1P, 4-[[3-(Piperazin-1-yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-10-4P, 4-[[3-(Piperidin-1-yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-12-6P, 4-[3-[[(2-Naphthyl)amino]methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-13-7P, 4-[3-[(3-Hydroxyphenylamino)methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-14-8P, 4-[3-[[(Quinolin-6-yl)amino]methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-15-9P, 4-[3-[(4-tert-Butylphenylamino)methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-16-0P, 4-[3-[(3-Chloro-4-fluorophenylamino)methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-17-1P, 4-[3-[(Benzylamino)methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-18-2P, 4-[3-[[(Pyridin-2-ylmethyl)amino]methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-19-3P, 4-[3-[(2,2-Diphenylethylamino)methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-20-6P, 4-[3-[(2-Hydroxyphenylamino)methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-21-7P, 4-[3-[[[3-(Benzyloxy)phenyl]amino]methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-22-8P, 4-[3-[(Phenylamino)methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-23-9P, 4-[3-[(2,3-Dihydroindol-1-yl)methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-24-0P,

4-[3-[[(Cyclohexylmethyl)amino]methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-25-1P, 4-[3-[(Phenethylamino)methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-27-3P, 1-[2-[[3-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)benzyl]amino]ethyl]pyrrolidinium acetate 870241-29-5P 870241-31-9P 870241-32-0P, Biphenyl-4-yl-[2-[(4-methylpiperazin-1-yl)methyl]thieno[2,3-c]pyridin-4-yl]amine 870241-38-6P, 4-[[1-(2-Methylbenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-39-7P, 4-[[1-(3-Methylbenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-40-0P, 4-[[1-(4-Methylbenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-41-1P, 4-[[1-(2-Cyanobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-42-2P, 4-[[1-(3-Cyanobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-43-3P, 4-[[1-(4-Cyanobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-44-4P, 4-[[1-(Cyclohexylmethyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-45-5P, 4-[(1-Phenethylpiperidin-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870241-46-6P, 4-[[1-[(Pyridin-2-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-47-7P, 4-[[1-[(Pyridin-3-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-48-8P, 4-[[1-[(Pyridin-4-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-49-9P, 4-[[1-[(3H-Imidazol-4-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-50-2P, 4-[[1-[(1-Methyl-1H-benzimidazol-2-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-51-3P, 4-[[1-[(1-Oxopyridin-4-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-52-4P, 4-[[1-[(5-Hydroxymethylfuran-2-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-53-5P, 4-[[1-(3-Methoxybenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-54-6P, 4-[[1-(4-Methoxybenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-55-7P, 4-[[1-[(Benzodioxol-5-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-56-8P, 4-[[1-[[5-(2-Chlorophenyl)furan-2-yl]methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-57-9P, 4-[[1-(4-Benzyloxybenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-58-0P, 4-[[1-(3,4-Dimethylbenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-59-1P, 4-[[1-[(Quinolin-2-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-60-4P, 4-[[1-(3,5-Dichlorobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-61-5P, 4-[[1-(2,5-Difluorobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-62-6P, 4-[[1-(3,5-Dimethylbenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-63-7P, 4-[[1-[[5-(3-Chlorophenyl)furan-2-yl]methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-64-8P, 4-[[1-(2,6-Difluorobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-65-9P, 4-[[1-(4-Phenoxybenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-66-0P, 4-[[1-(3,4-Dichlorobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-67-1P, 4-[[1-[[5-(2-Trifluoromethylphenyl)furan-2-yl]methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-68-2P, 4-[[1-(2,3-Difluorobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-69-3P, 4-[[1-(3,5-Difluorobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-72-8P, 4-[(Biphenyl-4-yl)amino]-7-carbamimidoylthieno[2,3-c]pyridine-2-carboxamide 870241-73-9P, 7-Amino-4-(biphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870241-77-3P, N-[4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]oxalamide 870241-78-4P, 4-[4-[[2-(4-Methylpiperazin-1-yl)acetyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-79-5P, 4-[4-[[2-(1,2,4-Triazol-1-yl)acetyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-80-8P, 4-[[1-(4-Nitrophenyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-

carboxamide 870241-81-9P, 4-[[1-(4,6-Dimethoxypyrimidin-2-yl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-82-0P, 4-[3-(Pyridin-3-yl)phenyl]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-87-5P, 2-(1H-Tetrazol-5-yl)-4-(6-trifluoromethylbiphenyl-3-yl)thieno[2,3-c]pyridine 870241-88-6P, 4-(6-Fluorobiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-89-7P, 4-(3'-Methylsulfonylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-90-0P, 4-(3'-Methoxybiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-91-1P, 4-(2'-Methoxybiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-92-2P, 4-(2'-Methylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-93-3P, 4-(3'-Nitrobiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-94-4P, 4-(3'-Methylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-95-5P, 4-(4'-Fluorobiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-96-6P, 4-(4'-Methylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-97-7P, 4-[3-(3,5-Dimethylisoxazol-4-yl)phenyl]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-98-8P, 3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-4-carbonitrile 870241-99-9P, 4-(4'-Methylsulfonylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-00-5P, [3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-3-yl]amine 870242-01-6P, 4-(2'-Fluorobiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-02-7P, 1-[3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-3-yl]ethanone 870242-03-8P, 2-(1H-Tetrazol-5-yl)-4-(3'-trifluoromethylbiphenyl-3-yl)thieno[2,3-c]pyridine 870242-04-9P, 1-[3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-4-yl]ethanone 870242-05-0P, 2-(1H-Tetrazol-5-yl)-4-(4'-trifluoromethylbiphenyl-3-yl)thieno[2,3-c]pyridine 870242-06-1P, 4-(3'-Fluorobiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-07-2P, 4-(4'-tert-Butylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-08-3P, 4-(3',4'-Dimethoxybiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-09-4P, Dimethyl[3'-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-4-yl]amine 870242-10-7P, 4-(4'-Ethylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-11-8P, 4-[3-(Benzo[b]thiophen-3-yl)phenyl]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-12-9P, 1-[3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-4-yl]methanol 870242-13-0P, 4-(3'-Cyanobiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-14-1P, N-[3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-3-yl]methanesulfonamide 870242-15-2P, 3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-3-ol 870242-16-3P, 1-[3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-2-yl]methanol 870242-17-4P, 4-[3-(Furan-3-yl)phenyl]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-18-5P, 4-(3'-Methylsulfanylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-19-6P, 3-[3-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]thiophene-2-carboxaldehyde 870242-20-9P, 3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-3-carboxamide 870242-21-0P, [3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-4-yl]amine 870242-22-1P, Dimethyl[[3'-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-2-yl]methyl]amine 870242-23-2P, 4-(4'-Nitrobiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-24-3P, [3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-2-yl]amine 870242-25-4P, Dimethyl[[3'-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-3-yl]methyl]amine 870242-26-5P, 4-(3'-Butoxybiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-27-6P, 4-(4'-Butoxybiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-28-7P, 3-Methoxy-3'-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-4-ol 870242-29-8P, 7-Amino-4-(3'-methylsulfonylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870242-30-1P, 7-Amino-4-[3-(benzo[b]thiophen-3-yl)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870242-31-2P, 7-Amino-4-(4'-ethylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870242-32-3P, 7-Amino-4-(3'-methylbiphenyl-3-

yl)thieno[2,3-c]pyridine-2-carboxamide 870242-33-4P, 7-Amino-4-(3',4'-dimethoxybiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870242-34-5P, 7-Amino-4-(3'-trifluoromethylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870242-35-6P, 7-Amino-4-(3'-aminobiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870242-36-7P 870242-37-8P, 7-Amino-4-(4'-carbamoylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870242-38-9P, 4-(4'-Acetylbiphenyl-3-yl)-7-aminothieno[2,3-c]pyridine-2-carboxamide 870242-39-0P, 7-Amino-4-(4'-cyanobiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870242-40-3P, 4-[(3'-Cyanobiphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-41-4P, 4-[[4-(Pyridin-4-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-42-5P, 4-[[4-(Thiophen-3-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-43-6P, 4-[[4-(Benzo[b]thiophen-3-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-44-7P, 4-[(3',5'-Dichlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-45-8P, 4-[(4'-Trifluoromethylbiphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-46-9P, 4-[(4'-Fluorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-47-0P, 4-[(4'-Chlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-48-1P, 4-[(3'-Methoxybiphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-49-2P, 4-[(2'-Chlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-50-5P, 4-[(3'-Chlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-51-6P, 4-[[4-(Benzodioxol-5-yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-52-7P, 4-[[4-(Naphthalen-1-yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-53-8P, 8-[4-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]phenyl]quinoline 870242-54-9P, 4'-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]biphenyl-3-carboxylic acid methyl ester 870242-55-0P, 2-(1H-Tetrazol-5-yl)-4-[(3'-trifluoromethyloxybiphenyl-4-yl)oxy]thieno[2,3-c]pyridine 870242-56-1P, 2-(1H-Tetrazol-5-yl)-4-[(3'-trifluoromethylbiphenyl-4-yl)oxy]thieno[2,3-c]pyridine 870242-57-2P, 4-[(3'-Nitrobiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-58-3P, [4'-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]biphenyl-3-yl]acetonitrile 870242-59-4P, 2-(1H-Tetrazol-5-yl)-4-[(4'-trifluoromethyloxybiphenyl-4-yl)oxy]thieno[2,3-c]pyridine 870242-60-7P, 4'-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]biphenyl-4-carbonitrile 870242-61-8P, 4-[(3',4'-Difluorobiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-62-9P, 2-(1H-Tetrazol-5-yl)-4-[(3',4',5'-trifluorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridine 870242-63-0P, 4-[(3',4'-Dichlorobiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-64-1P, 4-[(4'-Fluoro-3'-methylbiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-65-2P, 4-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-66-3P, 4-[(4'-Methyl-3'-nitrobiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-67-4P, 4'-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]biphenyl-3-carboxamide 870242-68-5P, 4-[(3'-Chloro-4'-fluorobiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-69-6P, 4-[(Biphenyl-3-yl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-70-9P, 4-[[4-(Benzodioxol-5-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-71-0P, 4-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenoxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-72-1P, 4-[(3',4'-Dimethoxybiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-73-2P, 4-[(2',3'-Dimethoxybiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-74-3P, 2-(1H-Tetrazol-5-yl)-4-[(3',4',5'-trimethoxybiphenyl-4-yl)oxy]thieno[2,3-c]pyridine **870242-75-4P**, 3-Methoxy-4'-[[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]biphenyl-4-ol 870242-76-5P, 4-[(2',5'-Dimethoxybiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-77-6P, 4-[(4'-Methylsulfonylbiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-78-7P, 4-[(4'-Methylsulfanylbiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-79-8P, 4-[[4-[(Pyridin-3-yl)ethynyl]phenyl]oxy]thieno[

2,3-c]pyridine-2-carboxamide 870242-80-1P, 4-[4-(Phenylethynyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide 870242-81-2P, 4-[[4-(Morpholin-4-yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-82-3P, 4-[[4-(Morpholin-4-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxylic acid 870242-83-4P, 4-[[4-(Morpholin-4-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-84-5P, 4-(4-Phenylaminophenoxy)thieno[2,3-c]pyridine-2-carboxamide 870242-85-6P, 4-[[4-(Pyrrolidin-1-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-86-7P, 4-[4-[(Indan-5-yl)amino]phenoxy]thieno[2,3-c]pyridine-2-carboxamide 870242-87-8P, 4-[4-(Cyclohexylamino)phenoxy]thieno[2,3-c]pyridine-2-carboxamide 870242-88-9P, 4-[[3-(Morpholin-4-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxylic acid 870242-89-0P, 4-[[3-(Morpholin-4-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-90-3P, 4-[3-[[(Dimethylamino)sulfonyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870242-91-4P, 4-[4-[[(4,5-Dibromothien-2-yl)sulfonyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870242-96-9P, 4-Amino-7-(biphenyl-3-yl)thieno[2,3-c]pyridine-3-carboxylic acid 870242-97-0P, 4-Phenylsulfonylthieno[2,3-c]pyridine-2-carboxamide 870242-98-1P, 4-Phenylsulfinylthieno[2,3-c]pyridine-2-carboxamide 870242-99-2P, 4-(Biphenyl-3-yl)-1H-pyrrolo[2,3-c]pyridine-2-carbonitrile 870243-09-7P, 4-(Biphenyl-3-yl)furo[2,3-c]pyridine-2-carboxylic acid 870243-11-1P, 3-[4-(4-Iodophenoxy)thieno[2,3-c]pyridin-2-yl]-2H-[1,2,4]oxadiazol-5-one 870243-12-2P, 3-[4-(4-Iodophenoxy)thieno[2,3-c]pyridin-2-yl]-2H-[1,2,4]thiadiazol-5-one 870243-14-4P
, 3-[4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]-2H-[1,2,4]oxadiazol-5-one 870243-15-5P, 4-(4-Iodophenoxy)-2-(5-phenyl-1H-imidazol-2-yl)thieno[2,3-c]pyridine 870243-16-6P, [2-[4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]-3H-imidazol-4-yl]methanol 870243-17-7P, 2-(1H-Benzimidazol-2-yl)-4-[(biphenyl-4-yl)oxy]thieno[2,3-c]pyridine 870243-19-9P 870243-20-2P, [3-[4-(4-Iodophenoxy)thieno[2,3-c]pyridin-2-yl]ureido]acetic acid ethyl ester 870243-22-4P, 1-[4-(4-Iodophenoxy)thieno[2,3-c]pyridin-2-yl]-3-phenylurea 870243-23-5P, 4-Fluorothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870243-24-6P, 4-Fluorothieno[2,3-c]pyridine-2-carboxylic acid N-(4-bromophenyl)amide 870243-25-7P, [4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]phenylmethanol 870243-26-8P, 2-(5-Benzyloxypyridin-3-yl)-4-[(biphenyl-4-yl)amino]thieno[2,3-c]pyridine 870243-30-4P, 4-[(Biphenyl-4-yl)amino]-7-chlorothieno[2,3-c]pyridine-2-carboxylic acid 870243-32-6P, 7-Amino-4-[(biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870243-33-7P, 4-[(3',5'-Dichlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxylic hydrazide 870243-35-9P, [4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]piperazin-1-ylmethanone 870243-36-0P 870243-38-2P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid N-(tert-butoxy)amide 870243-40-6P, 3-[[[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]carbonyl]amino]propionic acid monotrifluoroacetate 870243-41-7P, (R)-2-[[[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]carbonyl]amino]-3-hydroxypropionic acid 870243-43-9P, [4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]methanol 870243-44-0P, 4-[(4-Bromophenyl)(methyl)amino]thieno[2,3-c]pyridine-2-carboxamide 870243-45-1P, 4-Chlorobenzo[b]thiophene-2-carboxamide 870243-46-2P, 4-[(4'-Trifluoromethylbiphenyl-4-yl)oxy]thieno[2,3-c]pyridine 870243-47-3P, 4,7-Bis(biphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870243-48-4P 870243-50-8P, 4-[3-[(Carbamoylmethyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

IT 870243-52-0P, 4-(4-Iodophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid (2-dimethylaminoethyl)amide 870243-53-1P, 4-(4-Iodophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid

[3-(morpholin-4-yl)propyl]amide 870243-56-4P, [7-(Biphenyl-3-yl)thieno[3,2-c]pyridin-4-yl]amine 870243-57-5P, (Biphenyl-4-yl)[2-(2H-pyrazol-3-yl)thieno[2,3-c]pyridin-4-yl]amine 870243-58-6P, Thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870243-60-0P, 4-[(Biphenyl-4-yl)amino]-7-phenylthieno[2,3-c]pyridine-2-carboxamide 870243-61-1P, 4-[(Biphenyl-4-yl)amino]-7-methylthieno[2,3-c]pyridine-2-carboxamide 870243-62-2P, 4-[(Biphenyl-4-yl)amino]-7-(1H-pyrrol-2-yl)thieno[2,3-c]pyridine-2-carboxamide 870243-63-3P, 4-[(Biphenyl-4-yl)amino]-7-carbamoylthieno[2,3-c]pyridine-2-carboxylic acid 870243-65-5P, 4-[(Biphenyl-4-yl)amino]-7-cyanothieno[2,3-c]pyridine-2-carboxylic acid 870243-69-9P, 4-[[5-(Pyridin-2-yl)thiophen-2-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870243-73-5P, (Biphenyl-4-yl)[2-(5-isopropylamino-[1,2,4]oxadiazol-3-yl)thieno[2,3-c]pyridin-4-yl]amine 870243-74-6P 870243-77-9P, (Biphenyl-4-yl)[2-(4H-[1,2,4]triazol-3-yl)thieno[2,3-c]pyridin-4-yl]amine 870243-78-0P 870243-80-4P, (Biphenyl-4-yl)[2-(5-trifluoromethyl-4H-[1,2,4]triazol-3-yl)thieno[2,3-c]pyridin-4-yl]amine 870243-81-5P, 4-[4-[(Benzoxazol-2-yl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870243-82-6P, 4-[3-Fluoro-4-[(5-fluorobenzoxazol-2-yl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870243-83-7P, (Biphenyl-4-yl)[2-(3H-[1,2,3]triazol-4-yl)thieno[2,3-c]pyridin-4-yl]amine 870243-87-1P 870243-88-2P, 3-[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]-2-cyano-N-isopropyl-3-oxopropionamide 870243-90-6P, 5-[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]-3H-[1,3,4]oxadiazol-2-one 870243-91-7P, [2-(5-Amino-[1,3,4]oxadiazol-2-yl)thieno[2,3-c]pyridin-4-yl](biphenyl-4-yl)amine 870243-92-8P 870243-93-9P, [2-(5-Amino-2H-pyrazol-3-yl)thieno[2,3-c]pyridin-4-yl](biphenyl-4-yl)amine 870243-98-4P, 4-[[1-(2-Hydroxybenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870244-00-1P, 4-[[1-(Benzyloxycarbonyl)piperidin-4-yl]methyl]-7-chlorothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870244-03-4P, 7-Amino-4-bromothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870244-05-6P, 4-(4-Bromophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid (2-hydroxy-1-methylethyl)amide 870244-07-8P, 4-[(4-Benzylpiperazin-1-yl)carbonyl]thieno[2,3-c]pyridine-2-carboxamide 870244-09-0P 870244-12-5P, 3-[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]-1,1-dimethylurea 870244-14-7P, 1-[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]-1,4-dihydrotetrazol-5-one 870244-15-8P, [4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]urea 870244-16-9P 870244-18-1P, 5-[(Biphenyl-4-yl)methyl]imidazo[1,2-a]pyrazine-2-carboxylic acid 870244-19-2P, 3-[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]-4H-[1,2,4]oxadiazin-5-one 870244-20-5P, 2-[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]-4H-[1,3,4]oxadiazin-5-one 870244-22-7P 870244-25-0P, 5-Amino-4-(biphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870244-31-8P, 4-(4-Bromophenylamino)-3-methylthieno[2,3-c]pyridine-2-carboxamide 870244-32-9P, 4-(4-Bromophenylamino)-3-methylthieno[2,3-c]pyridine-2-carboxylic acid 870244-33-0P 870244-36-3P, Biphenyl-4-yl-(1H-pyrrolo[2,3-c]pyridin-4-yl)amine 870244-39-6P, 4-(Biphenyl-3-yl)-1-(2-carboxyethyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid 870244-40-9P, 4-(Biphenyl-3-yl)-1-(2-carbamoylethyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

IT 870239-24-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

IT 146838-30-4 150316-07-7
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of fused heterocycles as kinase inhibitors)

IT 372092-80-3, Protein kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of fused heterocycles as kinase, particularly COT and MK2 kinase, inhibitors)

IT 19099-93-5P, 4-Oxopiperidine-1-carboxylic acid benzyl ester 32380-70-4P, 2-(2-Hydroxypropoxy)isoindole-1,3-dione 77112-52-8P 87597-27-1P, 5-Bromoimidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester 138163-12-9P, 4-Methylenepiperidine-1-carboxylic acid benzyl ester 158609-08-6P, 3-Chloro-5-(methoxymethoxy)pyridine 252663-49-3P, [3-(Benzoylamino)phenyl]boronic acid 799293-91-7P, 4-Amino-3-bromo-7-iodothieno[3,2-c]pyridine 819056-67-2P, 1-Phenyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]urea 870234-98-3P, 3,5-Difluoropyridine-4-carboxaldehyde 870235-14-6P 870235-23-7P, 4-(Biphenyl-3-yl)thieno[2,3-c]pyridine 870235-31-7P, 2-[(Benzyloxycarbonyl)amino]-3-(3,5-dibromopyridin-4-yl)acrylic acid methyl ester 870235-35-1P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid N-methoxy-N-methylamide 870235-36-2P, 4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxaldehyde 870238-70-3P, 2-Phenyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide 870243-00-8P, 3-[(Biphenyl-4-yl)oxy]-5-bromopyridine-4-carboxaldehyde 870243-01-9P, 2-[(Benzyloxycarbonyl)amino]-3-[3-[(biphenyl-4-yl)oxy]-5-bromopyridin-4-yl]acrylic acid methyl ester 870243-03-1P, 3-Chloro-5-(methoxymethoxy)pyridine-4-carboxaldehyde 870243-04-2P, 5-Chloro-4-(dimethoxymethyl)pyridin-3-ol 870243-05-3P, [[5-Chloro-4-(dimethoxymethyl)pyridin-3-yl]oxy]acetic acid ethyl ester 870243-06-4P, [(5-Chloro-4-formylpyridin-3-yl)oxy]acetic acid ethyl ester 870243-28-0P, 4-Bromo-5-chlorothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870243-49-5P 870243-67-7P, 2-(2-tert-Butoxyethoxy)isoindole-1,3-dione 870243-68-8P, 4-[[5-(Pyridin-2-yl)thiophen-2-yl]amino]thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870243-71-3P, (Biphenyl-4-yl)[2-(5-trichloromethyl-[1,2,4]oxadiazol-3-yl)thieno[2,3-c]pyridin-4-yl]amine 870243-79-1P 870243-85-9P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870243-94-0P, (4-Bromothieno[2,3-c]pyridin-2-yl)methanol 870243-95-1P, 4-Bromo-7-oxo-6,7-dihydrothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870243-96-2P, 4-(Biphenyl-3-yl)-7-oxo-6,7-dihydrothieno[2,3-c]pyridine-2-carboxylic acid 870244-01-2P, 4-Vinylthieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870244-02-3P 870244-08-9P 870244-10-3P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid lithium salt 870244-13-6P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonyl chloride 870244-17-0P 870244-29-4P, 1-(3,5-Dibromopyridin-4-yl)ethanone 870244-35-2P 870244-38-5P, 4-Bromo-1-(2-methoxycarbonylethyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of fused heterocycles as kinase inhibitors)

IT 82249-72-7
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of fused heterocycles as inhibitors of pErk signaling resulting from lipopolysaccharides stimulation)

IT 55-22-1, Isonicotinic acid, reactions 63-74-1, 4-Aminobenzenesulfonamide 64-04-0, Phenethylamine 67-36-7, 4-Phenoxybenzaldehyde 67-47-0, 5-Hydroxymethylfuran-2-carboxaldehyde 70-11-1, Bromoacetophenone 79-30-1, Isobutyryl chloride 86-58-8, Quinolin-8-ylboronic acid 86-77-1, 2-Dibenzofuranol 88-18-6, 2-tert-Butylphenol 88-69-7, 2-Isopropylphenol 89-72-5, 2-sec-Butylphenol 89-83-8, Thymol 89-98-5, 2-Chlorobenzaldehyde 90-00-6, 2-Ethylphenol 90-15-3, 1-Naphthol 90-43-7, Biphenyl-2-ol 91-59-8, Naphthalen-2-ylamine 92-67-1, Biphenyl-4-ylamine 92-69-3, Biphenyl-4-ol 94-09-7, 4-Aminobenzoic acid ethyl ester 95-54-5, o-Phenylenediamine, reactions 95-55-6, 2-Aminophenol 95-65-8, 3,4-Dimethylphenol 95-76-1, 3,4-Dichloroaniline 95-87-4, 2,5-Dimethylphenol 96-26-4,

Dihydroxyacetone 96-70-8, 2-tert-Butyl-4-ethylphenol 98-27-1, 4-tert-Butyl-2-methylphenol 98-54-4, 4-tert-Butylphenol 98-80-6, Phenylboronic acid 99-92-3, 4'-Aminoacetophenone 99-98-9, N,N-Dimethyl-p-phenylenediamine 100-01-6, 4-Nitroaniline, reactions 100-07-2, 4-Methoxybenzoyl chloride 100-36-7, N,N-Diethylethylenediamine 100-59-4, Phenylmagnesium chloride 103-01-5, N-Phenylglycine 103-71-9, Phenyl isocyanate, reactions 103-80-0, Phenylacetyl chloride 104-53-0, 3-Phenylpropionaldehyde 104-85-8, 4-Methylbenzonitrile 104-87-0, 4-Methylbenzaldehyde 104-88-1, 4-Chlorobenzaldehyde, reactions 104-94-9, p-Anisidine 105-07-7, 4-Formylbenzonitrile 105-36-2, Ethyl bromoacetate 105-67-9, 2,4-Dimethylphenol 106-40-1, 4-Bromophenylamine 106-47-8, 4-Chloroaniline, reactions 106-49-0, p-Toluidine, reactions 108-00-9, N,N-Dimethylethylenediamine 108-23-6, Isopropyl chloroformate 108-39-4, m-Cresol, reactions 108-43-0, 3-Chlorophenol 108-68-9, 3,5-Dimethylphenol 108-91-8, Cyclohexylamine, reactions 109-01-3, 1-Methylpiperazine 109-85-3, 2-Methoxyethylamine 109-90-0, Ethyl isocyanate 110-72-5, N-Ethylethylenediamine 120-57-0, 1,3-Benzodioxole-5-carboxaldehyde 122-78-1, Phenylacetaldehyde 123-00-2, N-(3-Aminopropyl)morpholine 123-11-5, 4-Methoxybenzaldehyde, reactions 135-02-4, 2-Methoxybenzaldehyde 139-59-3, 4-Phenoxyphenylamine 140-31-8, N-(2-Aminoethyl)piperazine 150-19-6, 3-Methoxyphenol 156-43-4 156-87-6, 3-Aminopropan-1-ol 288-13-1, 1H-Pyrazole 320-51-4, (4-Chloro-3-trifluoromethylphenyl)amine 329-01-1, 1-Isocyanato-3-trifluoromethylbenzene 350-46-9, 1-Fluoro-4-nitrobenzene 367-21-5, 3-Chloro-4-fluoroaniline 367-24-8, 4-Bromo-2-fluoroaniline 371-40-4, 4-Fluoroaniline 393-11-3, 5-Amino-2-nitrobenzotrifluoride 437-81-0, 2,6-Difluorobenzaldehyde 447-61-0, 2-Trifluoromethylbenzaldehyde 454-89-7, 3-Trifluoromethylbenzaldehyde 455-14-1, 4-Aminobenzotrifluoride 455-19-6, 4-Trifluoromethylbenzaldehyde 461-82-5, 4-(Trifluoromethoxy)aniline 496-15-1, Indoline 500-22-1, 3-Pyridinecarboxaldehyde 500-99-2, 3,5-Dimethoxyphenol 504-24-5, Pyridin-4-ylamine 524-38-9, 2-Hydroxyisoindole-1,3-dione 526-75-0, 2,3-Dimethylphenol 529-19-1, 2-Methylbenzonitrile 529-20-4, 2-Methylbenzaldehyde 529-35-1, 5,6,7,8-Tetrahydro-1-naphthol 536-74-3, Phenylacetylene 539-74-2, 3-Bromopropionic acid ethyl ester 540-38-5, 4-Iodophenol 576-26-1, 2,6-Dimethylphenol 577-92-4, 4-tert-Butyl-2-phenylphenol 580-15-4, 6-Aminoquinoline 583-75-5, (4-Bromo-2-methylphenyl)amine 585-34-2, 3-tert-Butylphenol 587-04-2, 3-Chlorobenzaldehyde 589-16-2, 4-Ethylaniline 591-27-5, 3-Aminophenol 591-31-1, 3-Methoxybenzaldehyde 591-54-8, 4-Aminopyrimidine 599-64-4, 4-Cumylphenol 613-45-6, 2,4-Dimethoxybenzaldehyde 614-68-6, o-Tolyl isocyanate 618-45-1, 3-Isopropylphenol 620-17-7, 3-Ethylphenol 620-22-4, 3-Methylbenzonitrile 620-23-5, 3-Methylbenzaldehyde 621-29-4, m-Tolyl isocyanate 621-34-1, 3-Ethoxyphenol 622-58-2, p-Tolyl isocyanate 625-92-3, 3,5-Dibromopyridine 645-45-4, 3-Phenylpropionyl chloride 656-65-5, 4-Bromo-3-fluoroaniline 698-71-5, 3-Ethyl-5-methylphenol 713-68-8, 3-Phenoxyphenol 716-96-1, 2-Benzyl-4-methylphenol 768-35-4, 3-Fluorophenylboronic acid 769-92-6, 4-tert-Butylaniline 782-45-6, 4-Aminobenzanilide 831-82-3, 4-Phenoxyphenol 872-85-5, 4-Pyridinecarboxaldehyde 873-62-1, 3-Cyanophenol 873-74-5, 4-Aminobenzonitrile 874-42-0, 2,4-Dichlorobenzaldehyde 876-33-5 1121-60-4, 2-Pyridinecarboxaldehyde 1125-66-2, 4-Chloro-3-ethyl-5-methylphenol 1138-52-9, 3,5-Di-tert-butylphenol 1195-09-1, 2-Methoxy-5-methylphenol 1423-26-3, (3-Trifluoromethylphenyl)boronic acid 1484-26-0, 3-Benzyloxyaniline 1489-69-6, Cyclopropanecarboxaldehyde 1490-25-1, 3-Chlorocarbonylpropionic acid methyl ester 1518-83-8, 4-Cyclopentylphenol 1518-84-9, 2-Cyclopentylphenol 1520-21-4, 4-Aminostyrene 1548-13-6, 1-Isocyanato-4-trifluoromethylbenzene 1570-64-5, 4-Chloro-2-methylphenol 1679-18-1, 4-Chlorophenylboronic acid 1692-15-5, Pyridin-4-ylboronic acid 1692-25-7, Pyridin-3-ylboronic acid 1711-11-1, 3-Cyanobenzoyl chloride 1765-93-1, 4-Fluorophenylboronic acid 1795-48-8, Isopropyl

isocyanate 1885-14-9, Phenyl chloroformate 1899-93-0, m-Toluenesulfonyl chloride 1993-03-9, 2-Fluorophenylboronic acid 2033-89-8, 3,4-Dimethoxyphenol 2038-03-1, N-(2-Aminoethyl)morpholine 2043-61-0, Cyclohexanecarboxaldehyde 2219-78-5, 3,4-Dimethyl-6-ethylphenol 2221-00-3, [4-(Imidazol-1-yl)phenyl]amine 2237-30-1, 3-Aminobenzonitrile 2243-47-2, [1,1'-Biphenyl]-3-amine 2251-65-2, m-(Trifluoromethyl)benzoyl chloride 2285-12-3, 1-Isocyanato-2-trifluoromethylbenzene 2359-60-6, 4-(Piperidin-1-yl)phenylamine 2365-48-2, Methyl thioglycolate 2439-04-5, 5-Hydroxyisoquinoline 2510-23-8, 3-Ethynylpyridine 2524-67-6, 4-(Morpholin-4-yl)phenylamine 2563-07-7, 2-Ethoxy-4-methylphenol 2646-91-5, 2,3-Difluorobenzaldehyde 2687-43-6, O-Benzylhydroxylamine hydrochloride 2759-28-6, 1-Benzylpiperazine 2949-22-6, Isocyanatoacetic acid ethyl ester 2963-77-1, 4-(1H-Benzimidazol-2-yl)phenylamine 3012-80-4, 1-Methyl-1H-benzimidazole-2-carboxaldehyde 3034-50-2, 3H-Imidazole-4-carboxaldehyde 3218-02-8, Aminomethylcyclohexane 3228-03-3, 5-Isopropyl-3-methylphenol 3544-25-0, 4-Aminobenzyl cyanide 3586-12-7, 3-Phenoxyphenylamine 3731-51-9, 2-(Aminomethyl)pyridine 3769-41-3, 3-Benzyloxyphenol 3795-76-4 3839-39-2 3900-89-8, 2-Chlorophenylboronic acid 3963-62-0, 2,2-Diphenylethylamine 4347-31-3, (2-Formylthien-3-yl)boronic acid 4397-53-9, 4-Benzyloxybenzaldehyde 4469-80-1, 4-Propoxyphenylamine 4688-76-0, Biphenyl-2-ylboronic acid 4747-71-1, Cyclopentyl isocyanate 4755-77-5, Ethyl oxalyl chloride 4760-58-1 4812-20-8, 2-Isopropoxyphenol 4854-84-6, 4'-Aminobiphenyl-4-carbonitrile 5049-61-6, Aminopyrazine 5122-94-1, (1,1'-Biphenyl-4-yl)boronic acid 5122-95-2, Biphenyl-3-ylboronic acid 5150-42-5, 2,3-Dimethoxyphenol 5192-03-0, 5-Aminoindole 5271-67-0, 2-Thiophenecarbonyl chloride 5392-82-5 5402-37-9, 4-(1-Indanyl)phenol 5555-48-6 5625-67-2, Piperazinone 5720-05-8, 4-Methylphenylboronic acid 5720-06-9, 2-Methoxyphenylboronic acid 5720-07-0, 4-Methoxyphenylboronic acid 6084-58-8, O-Isobutylhydroxylamine hydrochloride 6165-69-1, Thien-3-ylboronic acid 6287-38-3, 3,4-Dichlorobenzaldehyde 6315-89-5, 3,4-Dimethoxyphenylamine 6361-22-4, 2-Chloro-6-nitrobenzaldehyde 6373-50-8, (4-Cyclohexylphenyl)amine 6914-76-7, 1-Methylcyclopropanecarboxylic acid 6949-73-1, 2-Hydroxyfluoren-9-one 7154-73-6, 1-(2-Aminoethyl)pyrrolidine 7216-42-4, N-Oxopyridine-4-carboxaldehyde 7468-67-9, 2-Formylbenzonitrile 7570-49-2, 5-Amino-2-methylindole 7580-85-0, 2-tert-Butoxyethanol 10199-50-5, (2-Methyl-5-phenyl-2H-pyrazol-3-yl)amine 10365-98-7, 3-Methoxyphenylboronic acid 10400-19-8, 3-Pyridinecarbonyl chloride 13035-19-3, Piperidin-4-ylamine 13223-25-1, 2-Chloro-4,6-dimethoxypyrimidine 13258-63-4, 4-(2-Aminoethyl)pyridine 13296-04-3, 4-(Pyridin-4-yl)phenylamine 13331-27-6, 3-Nitrophenylboronic acid 13382-43-9, 5-Amino-2-methylbenzothiazole 13922-41-3, Naphthalen-1-ylboronic acid 14047-29-1, 4-Carboxyphenylboronic acid 14254-57-0, 4-Pyridinecarbonyl chloride 14268-66-7, 3,4-(Methylenedioxy)aniline 16024-55-8, (2-Methoxyethoxy)acetyl chloride 16114-47-9, (3,5-Dimethylisoxazol-4-yl)boronic acid 16419-60-6, o-Tolylboronic acid 16629-19-9, 2-Thiophenesulfonyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of fused heterocycles as kinase inhibitors)

IT 17933-03-8, 3-Methylphenylboronic acid 18542-42-2, 2-(Methylthio)ethylamine 19438-10-9, Methyl 3-hydroxybenzoate 19992-45-1, (4-Phenylcyclohexyl)amine 20291-99-0, tert-Butyl thioglycolate 21485-78-9, Methyl[2-(methylsulfanyl)ethyl]amine 21615-34-9, 2-Methoxybenzoyl chloride 22013-33-8, 3,4-Ethylenedioxyaniline 22236-10-8, 4-(Difluoromethoxy)aniline 23159-07-1, 1-(3-Aminopropyl)pyrrolidine 24067-17-2, 4-Nitrophenylboronic acid 24424-99-5, tert-Butoxycarbonyl anhydride 24425-40-9, 5-Aminoindan 24964-64-5, 3-Formylbenzonitrile 25054-53-9, Benzodioxole-5-carbonyl chloride 25487-66-5, (3-Carboxyphenyl)boronic acid 27292-49-5, 3-(Morpholin-4-yl)phenol 27292-50-8,

3-Piperidinophenol 27578-60-5, 1-(2-Aminoethyl)piperidine 28611-39-4, [4-(N,N-Dimethylamino)phenyl]boronic acid 28994-41-4, 2-Hydroxydiphenylmethane 29236-47-3, 2-Bromoethyl pyruvate 29605-78-5 29668-44-8, 2,3-Dihydrobenzo[1,4]dioxin-6-carboxaldehyde 29745-44-6, 2-Pyridinecarbonyl chloride 30418-59-8, 3-Aminophenylboronic acid 31301-45-8, 3,5-Dimethylisoxazole-4-carbonyl chloride 32085-88-4, 3,5-Difluorobenzaldehyde 32316-92-0, Naphthalen-2-ylboronic acid 33421-40-8, (5-Phenylpyridin-2-yl)amine 34035-04-6, 5-(2-Chlorophenyl)furan-2-carboxaldehyde 34893-92-0, 1,3-Dichloro-5-isocyanatobenzene 36716-44-6 37527-66-5, 4-Isocyanato-1,2-dimethoxybenzene 38870-89-2, 2-Methoxyacetyl chloride 38936-62-8 38945-21-0, O-Allylhydroxylamine hydrochloride 39684-28-1, O-tert-Butylhydroxylamine hydrochloride 39920-37-1 40972-86-9, (2,3-Dimethoxyphenyl)boronic acid 41253-21-8, 1,2,4-Triazole sodium salt 41463-83-6, Trifluoromethylacetyl chloride 41979-39-9, 4-Piperidone hydrochloride 42058-59-3, (3-Hydroxyphenyl)acetic acid methyl ester 50541-93-0, (1-Benzylpiperidin-4-yl)amine 51067-38-0, 4-Phenoxyphenylboronic acid 51387-90-7, 2-(2-Aminoethyl)-1-methylpyrrolidine 51537-21-4, O-tert-Butyl-L-serine tert-butyl ester hydrochloride 51552-16-0, Dimethylaminoacetyl chloride 55552-70-0, Furan-3-ylboronic acid 57260-71-6, tert-Butyl 1-piperazinecarboxylate 57688-34-3, (4'-Trifluoromethylbiphenyl-4-yl)amine 58620-93-2 59016-93-2, (4-Hydroxymethylphenyl)boronic acid 59084-16-1, 1-Acetylpiperidine-4-carbonyl chloride 59817-32-2, 1-(3-Hydroxyphenyl)piperazine 62348-13-4, Isoxazole-5-carbonyl chloride 62368-29-0, 1-Acetyl-6-amino-2,3-dihydro-1H-indole 63019-97-6, (2-Methylbiphenyl-4-yl)amine 63139-21-9, 4-Ethylphenylboronic acid 63503-60-6, 3-Chlorophenylboronic acid 63921-23-3, 1-Phenylpiperidin-4-amine 66472-86-4, 3-Aminophenylboronic acid hemisulfate 67492-50-6, (3,5-Dichlorophenyl)boronic acid 68792-12-1, 3-Isopropoxyphenol 69922-27-6, 2-Fluoro-5-(trifluoromethyl)phenyl isocyanate 70201-42-2, 3,5-Dibromopyridine-4-carboxaldehyde 71597-85-8, 4-Hydroxyphenylboronic acid 71902-33-5, 3,5-Difluoropyridine 73183-34-3, Diboron pinacol ester 74115-12-1, 3-Chloropyridin-5-ol 75315-63-8 80500-27-2, 4-Methyl-3-nitrophenylboronic acid 81606-31-7, 4,5-Dibromothiophene-2-sulfonyl chloride 83947-56-2 84358-13-4, N-(tert-Butoxycarbonyl)piperidine-4-carboxylic acid 85107-53-5, [2-[(N,N-Dimethylamino)methyl]phenyl]boronic acid 85199-06-0, (2,5-Dimethylphenyl)boronic acid 86732-22-1, 2-Benzyloctahydropyrrolo[3,4-c]pyrrole 87120-72-7 87199-14-2, (2-Hydroxymethylphenyl)boronic acid 87199-15-3, (3-Hydroxymethylphenyl)boronic acid 87199-16-4, 3-Formylphenylboronic acid 87199-17-5, 4-Formylphenylboronic acid 87199-18-6, 3-Hydroxyphenylboronic acid 88568-95-0, N-(Benzyloxycarbonyl)-α-phosphonoglycine trimethyl ester 89415-43-0, 4-Aminophenylboronic acid 89711-08-0, tert-Butyl N-(2-oxoethyl)carbamate 90555-66-1, 3-Ethoxyphenylboronic acid 94098-56-3, 5-(2-Trifluoromethylphenyl)furan-2-carboxaldehyde 94839-07-3, (3,4-Methylenedioxyphenyl)boronic acid 96901-92-7, (8-Benzyl-8-azabicyclo[3.2.1]oct-3-yl)amine 98437-23-1, (Benzo[b]thien-2-yl)boronic acid 98437-24-2, (Benzo[b]furan-2-yl)boronic acid 99769-19-4, 3-Methoxycarbonylphenylboronic acid 100444-43-7, 2,6-Dimethylbiphenyl-4-ol 105365-51-3 107099-99-0, (2,5-Dimethoxyphenyl)boronic acid 108238-09-1, 2-Phenoxyphenylboronic acid 110952-48-2, 4-Amino-2-[(dimethylamino)methyl]phenol 113893-08-6, (Benzo[b]thien-3-yl)boronic acid 114474-28-1, 4-(1H-Pyrazol-4-yl)phenylamine 121219-16-7, (2,3-Difluorophenyl)boronic acid 122775-35-3, (3,4-Dimethoxyphenyl)boronic acid 123088-59-5, 4-Aminocarbonylphenylboronic acid 123324-71-0, 4-tert-Butylphenylboronic acid 123784-07-6, 2-(5-Bromothiophen-2-yl)pyridine 126747-14-6, 4-Cyanophenylboronic acid 126917-10-0, 2-Fluoro-4-trifluoromethylbenzoyl chloride 128312-11-8, 3-Methylsulfanylphenylboronic acid 128796-39-4, (4-Trifluoromethylphenyl)boronic acid 129271-98-3, [1-(Phenylsulfonyl)-1H-indol-3-yl]boronic acid 130722-95-1, 3-Benzyloxy-5-bromopyridine

135884-31-0, [1-(tert-Butoxycarbonyl)pyrrol-2-yl]boronic acid 136590-83-5, 3,5-Dichloropyridine-4-carboxaldehyde 138642-62-3, 2-Cyanophenylboronic acid 139301-27-2, (4-Trifluoromethoxyphenyl)boronic acid 139911-27-6, (4-Fluoro-3-methylphenyl)boronic acid 143418-49-9, (3,4,5-Trifluorophenyl)boronic acid 144432-85-9, 3-Chloro-4-fluorophenylboronic acid 146631-00-7, (4-Benzyloxyphenyl)boronic acid 147081-49-0, (R)-3-Aminopyrrolidine-1-carboxylic acid tert-butyl ester 148355-75-3, [3-[(Methylsulfonyl)amino]phenyl]boronic acid 148839-33-2, (5-Chloro-2-methylphenyl)boronic acid 149104-88-1, 4-(Methylsulfonyl)phenylboronic acid 149104-90-5, 4-Acetylphenylboronic acid 149507-26-6, (3-Fluoro-4-methoxyphenyl)boronic acid 150255-96-2, 3-Cyanophenylboronic acid 151169-75-4, (3,4-Dichlorophenyl)boronic acid 156682-54-1, (3-Benzyloxyphenyl)boronic acid 160521-46-0, 3'-Bromobiphenyl-4-carbonitrile 164014-95-3, (1,4-Benzodioxan-6-yl)boronic acid 168267-41-2, (3,4-Difluorophenyl)boronic acid 175205-54-6, 2-Chloro-4-trifluoromethylbenzenesulfonyl chloride 175676-65-0, [2-(Trifluoromethoxy)phenyl]boronic acid 175883-63-3, (3-Chloro-4-methylphenyl)boronic acid 178305-99-2, (2-Fluorobiphenyl-4-yl)boronic acid 179113-90-7, [3-(Trifluoromethoxy)phenyl]boronic acid 179897-94-0, 5-Fluoro-2-methoxyphenylboronic acid 182163-96-8, (3,4,5-Trimethoxyphenyl)boronic acid 182281-01-2, 4-Hydroxyphenylboronic acid tetrahydropyranyl ether 190661-29-1, (2-Benzyloxyphenyl)boronic acid 191171-55-8, 2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 192182-55-1, (N-Methylindol-5-yl)boronic acid 193269-78-2, 3-Aminoazetidine-1-carboxylic acid tert-butyl ester 195062-61-4, 2-(4-Chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 197507-55-4, 8-Bromo-[1,6]naphthyridine-2-carboxylic acid 204841-19-0, 3-Acetylphenylboronic acid 214360-60-8 214360-73-3, 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenylamine 216019-28-2, 3-Isopropylphenylboronic acid 227305-69-3, (2,3-Dihydrobenzo[b]furan-5-yl)boronic acid 251993-29-0, 4-(3-Bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide 251994-31-7, 4-(4-Aminophenoxy)thieno[2,3-c]pyridine-2-carboxamide 251996-00-6, 4-(4-Bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide 251996-52-8, 4-(4-Iodophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 251997-23-6, 4-(3-Chlorophenyl)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 269410-08-4, 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 269410-22-2, 2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 279261-81-3, 3-Chloro-4-ethoxyphenylboronic acid 279261-89-1, (3,4-Dihydro-2H-1,5-bezodioxepin-7-yl)boronic acid 317821-72-0 330793-73-2, (Benzoxazol-2-yl)[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]amine 351422-73-6, (3-Aminocarbonylphenyl)boronic acid 352303-67-4, 2-Fluoro-3-methoxyphenylboronic acid 352534-81-7, 3-Butoxyphenylboronic acid 352534-86-2, 5-Chloro-2-ethoxyphenylboronic acid 370881-68-8, (1R,5R)-3,6-Diazabicyclo[3.2.0]heptane-3-carboxylic acid benzyl ester 373384-18-0, 3-(Methylsulfonyl)phenylboronic acid 396131-82-1 400605-33-6 443998-73-0, (3'-Cyanobiphenyl-4-yl)amine 461699-49-0, (5-Methylbenzoxazol-2-yl)[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amine 479719-88-5, 5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2,2'-bithiophene 499769-97-0 716324-44-6, 2-Benzyl-2,8-diazaspiro[4.5]decan-1-one 775351-54-7, 2-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile 819849-22-4, [3-[(N,N-Dimethylamino)methyl]phenyl]boronic acid 834884-74-1, [4-(Thiophen-3-yl)phenyl]amine 862729-59-7, (5-Fluorobenzoxazol-2-yl)[2-fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]amine 870235-04-4, 4-(4-Bromophenylamino)thieno[2,3-c]pyridine-2-carbonitrile 870235-26-0, 4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridine 870235-30-6, 4-[[4-(Thiophen-3-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870235-37-3, 4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxylic acid N-methoxy-N-methylamide 870235-39-5, [4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]amine 870235-47-5, 4-[(Biphenyl-4-yl)amino]-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid

methyl ester monotrifluoroacetate 870235-54-4, 4-(4-tert-Butylphenylamino)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-56-6, 3'-(7-Amino-2-carbamoylthieno[2,3-c]pyridin-4-yl)biphenyl-4-carboxylic acid methyl ester 870235-58-8, 7-Amino-4-(3',4'-dimethoxybiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-60-2, 7-Amino-4-(4'-carbamoylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-62-4, 7-Amino-4-(4'-methoxybiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-64-6, 7-Amino-4-[3-(benzo[b]thiophen-3-yl)phenyl]thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-66-8, 7-Amino-4-(4'-ethylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-68-0, 7-Amino-4-[3-(pyridin-4-yl)phenyl]thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-70-4, 7-Amino-4-(3'-methylsulfonylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-72-6, 4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-74-8, 5-[(Biphenyl-3-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-84-0, 4-[(3,5-Dimethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870235-86-2, 4-[(3-Fluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870235-88-4, 4-[(3-Chlorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870235-90-8, 4-[(3-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870235-92-0, 4-[(2-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870235-94-2, 4-[(3-Methylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870235-97-5, 4-[(2-Chlorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870235-99-7, 4-[(3,5-Difluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870236-11-6, 4-[(3-Methoxybiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870236-13-8, 4-(3-Chlorophenylamino)thieno[2,3-c]pyridine-2-carbonitrile 870236-20-7, 4-(4-Hydroxyphenylamino)thieno[2,3-c]pyridine-2-carbonitrile 870236-22-9, 4-(4-Aminophenylamino)thieno[2,3-c]pyridine-2-carbonitrile 870236-24-1, 4-(2-Cyanothieno[2,3-c]pyridin-4-yl)benzoic acid 870236-30-9, 4-(Cyclohexylamino)thieno[2,3-c]pyridine-2-carbonitrile 870236-32-1, 4-(4-Phenylcyclohexylamino)thieno[2,3-c]pyridine-2-carbonitrile 870236-34-3, 4-[(1-Benzylpiperidin-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870236-37-6, (1R,5R)-6-(2-Cyanothieno[2,3-c]pyridin-4-yl)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylic acid benzyl ester 870236-39-8, 4-[(4'-Formylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870236-41-2, 4-[(2-Cyanothieno[2,3-c]pyridin-4-yl)amino]piperidine-1-carboxylic acid tert-butyl ester 870236-43-4, (R)-3-[(2-Cyanothieno[2,3-c]pyridin-4-yl)amino]pyrrolidine-1-carboxylic acid tert-butyl ester 870236-45-6, 4-((3AS,6aR)-5-Benzylhexahydropyrrolo[3,4-c]pyrrol-2-yl)thieno[2,3-c]pyridine-2-carbonitrile 870236-47-8, 4-(2-Benzyloctahydropyrrolo[3,4-c]pyridin-5-yl)thieno[2,3-c]pyridine-2-carbonitrile 870236-49-0, 4-(2-Benzyl-1-oxo-2,8-diazaspiro[4.5]decan-8-yl)thieno[2,3-c]pyridine-2-carbonitrile 870236-51-4, 4-(1-Oxo-2-phenyl-2,8-diazaspiro[4.5]decan-8-yl)thieno[2,3-c]pyridine-2-carbonitrile 870236-53-6, (1R,4S)-5-(2-Cyanothieno[2,3-c]pyridin-4-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 870236-59-2, 4-Bromothieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870237-33-5, (3aR,7aR)-2-Benzyloctahydropyrrolo[3,4-c]pyridine 870237-35-7, (1R,4S)-2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 870238-20-3, [2-Chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamic acid 870238-36-1, 5-Chloro-2-formylphenylboronic acid 870238-40-7, 4-(Biphenyl-3-yl)-7-chlorothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870238-41-8, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine 870238-45-2, 4-(4-Bromophenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-65-6, 4,4,5,5-Tetramethyl-2-[4-[(trimethylsilanyl)ethynyl]phenyl]-1,3,2-dioxaborolane 870238-67-8, 2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile 870238-84-9 870239-36-4,

4-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]benzoic acid 870239-54-6, 4-[(Piperidin-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870239-77-3, [4-(4'-Methoxybiphenyl-3-yl)thieno[2,3-c]pyridin-2-yl]amine 870240-04-3, N'-(4-tert-Butylphenyl)thieno[2,3-c]pyridine-2,4-diamine 870240-13-4, 7-Amino-4-(3'-trifluoromethylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of fused heterocycles as kinase inhibitors)

IT 870240-18-9, 7-Amino-4-(4'-cyanobiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870240-39-4 870240-52-1, O-(2-tert-Butylethyl)hydroxyamine 870241-70-6, 7-Amino-4-(biphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870241-75-1, (1R,4S)-5-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 870241-76-2, 4-Bromo-7-chlorothieno[2,3-c]pyridine-2-carboxamide 870241-83-1, 4-(3-Chlorophenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-84-2, 4-(3-Chloro-4-trifluoromethylphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-85-3, 4-(3-Chloro-4-fluorophenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-86-4, 4-(3-Chloro-4-methoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-93-6, (3-Bromothieno[2,3-c]pyridin-4-yl)amine 870243-02-0, (Z)-2-[(Benzyloxycarbonyl)amino]-3-[3-[(biphenyl-4-yl)oxy]-5-bromopyridin-4-yl]-2-propenoic acid methyl ester 870243-21-3 870243-34-8, 2-[[4-[(3',5'-Dichlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]carbonyl]hydrazinecarboxylic acid tert-butyl ester 870243-42-8 870243-54-2, 4-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)benzoic acid ethyl ester 870243-55-3, [7-(Biphenyl-3-yl)-3-bromothieno[3,2-c]pyridin-4-yl]amine 870243-59-7, 7-[(Biphenyl-4-yl)amino]-4-bromothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870243-66-6 870243-72-4, 4-[(Biphenyl-4-yl)amino]-N-hydroxythieno[2,3-c]pyridine-2-carboximidamide 870243-76-8, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870243-97-3 870243-99-5, 4-[[1-(2-Methoxybenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870244-04-5, 7-[(Benzhydrylidene)amino]-4-bromothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870244-06-7 870244-21-6, N'-(2-Chloroacetyl)-4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic hydrazide 870244-23-8, (Ethylamino)[[[[4-[(4-phenylphenyl)amino]thieno[2,3-c]pyridin-2-yl]carbonyl]amino]amino]methanone 870244-34-1, 3,5-Dibromoisonicotinonitrile
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of fused heterocycles as kinase inhibitors)

IT 870244-26-1P, 5-Chloro-4-(biphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of fused heterocycles as kinase inhibitors)

ALL ANSWERS HAVE BEEN SCANNED

=> d cbib abs hitstr 1-2

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
2005:1240986 Document No. 144:22906 Preparation of fused heterocycle kinase inhibitors for treatment of protein tyrosine kinase-related diseases. Cusack, Kevin; Salmeron-Garcia, Jose-Andres; Gordon, Thomas D.; Barberis, Claude E.; Allen, Hamish J.; Bischoff, Agniezka K.; Ericsson, Anna M.; Friedman, Michael M.; George, Dawn M.; Roth, Gregory P.; Talanian, Robert V.; Thomas, Christine; Wallace, Grier A.; Wishart, Neil; Yu, Zhengtian (Abbott Laboratories, USA). PCT Int. Appl. WO 2005110410 A2 20051124, 362 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG,

NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-US16903 20050513. PRIORITY: US 2004-571281P 20040514.

GI



I



II

AB The invention is related to the preparation of fused heterocycles of formula I [A, B = independently N, S, O, a bond, etc.; D = C, N, S, O, C:C; U, V, W = independently CH and derivs., N; Y = a bond, CONH2 and derivs., SO, etc.; Z = H, halo, CN, etc.; X1 = a bond, halo, O, SO, NHSO2, etc.; R1 = a bond, (un)substituted benzofuranyl, benzimidazolyl, pyrrolyl, etc.; when R1 is not a bond, then X2 = a bond, O,S, NHCO and derivs., aliphatic group, etc.; or when R1 = a bond, then X2 = a bond and R2 is not a bond; R2 = a bond or (un)substituted benzoxazolyl, Ph, etc.; with provisos; and with the exception of certain compds.], and their pharmaceutically acceptable salts as inhibitors of kinases, particularly COT or MK2 kinases. The invention is also related to the use of certain compds. I as inhibitors of angiogenic receptor tyrosine kinases. Thus, reacting 4-(3-aminophenyl)thieno[2,3-c]pyridine-2-carboxamide with cyclopropanecarboxaldehyde gave thienopyridine II. All compds. I significantly inhibit either COT or MK2 at concns. of 50 μM or below.

IT **870242-75-4P**, 3-Methoxy-4'-[[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]biphenyl-4-ol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

RN 870242-75-4 CAPLUS

CN [1,1'-Biphenyl]-4-ol, 3-methoxy-4'-[[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]- (9CI) (CA INDEX NAME)



L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
2004:1154700 Document No. 142:75325 Epoxy compound and amine-cured epoxy resin product. Tanaka, Shinya; Takezawa, Yoshitaka; Takahashi, Hiroyuki (Sumitomo Chemical Company, Limited, Japan; Hitachi, Ltd.). PCT Int. Appl. WO 2004113327 A1 20041229, 64 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-JP8934 20040618. PRIORITY: JP 2003-174545 20030619.

AB The epoxy compound, which can be converted into a cured epoxy resin product having liquid crystal properties is obtained by curing with amine (or phenol) curing agent. Since the cured epoxy resin product exhibits good heat conductivity, it is also useful as an insulating material requiring high heat releasability such as a printed circuit substrate and the like. An example resin precursor 2,6-bis[4-[4-(oxiranylmethoxy)phenyl]phenoxy]pyridine had m.p. 157-160°.

IT **815600-54-5P**
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(pyridine condensate epoxy compound and cured epoxy resin product)

RN 815600-54-5 CAPLUS

CN [1,1'-Biphenyl]-4-ol, 4'-[(6-chloro-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)



IT **815600-55-6P**
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(reaction with epichlorohydrin; pyridine condensate epoxy compound and

10560891

cured epoxy resin product)
RN 815600-55-6 CAPLUS
CN [1,1'-Biphenyl]-4-ol, 4'-[[6-(4-hydroxyphenoxy)-2-pyridinyl]oxy]- (9CI)
(CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 14:32:41 ON 16 MAY 2007)

FILE 'REGISTRY' ENTERED AT 14:33:10 ON 16 MAY 2007
L1 STRUCTURE UPLOADED

FILE 'STNGUIDE' ENTERED AT 14:36:46 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 14:37:38 ON 16 MAY 2007
L2 STRUCTURE UPLOADED

FILE 'STNGUIDE' ENTERED AT 14:38:22 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 14:44:02 ON 16 MAY 2007
L3 STRUCTURE UPLOADED
L4 0 S L3
L5 0 S L3 FULL

FILE 'STNGUIDE' ENTERED AT 14:45:20 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 14:49:07 ON 16 MAY 2007
L6 STRUCTURE UPLOADED
L7 0 S L6
L8 5 S L7 FULL

FILE 'CAPLUS' ENTERED AT 14:50:31 ON 16 MAY 2007
L9 1 S L8

FILE 'STNGUIDE' ENTERED AT 14:52:57 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 14:57:15 ON 16 MAY 2007
L10 STRUCTURE UPLOADED
L11 0 S L10
L12 4 S L10 FULL

FILE 'CAPLUS' ENTERED AT 15:00:41 ON 16 MAY 2007
L13 2 S L12

=> sel an l13 2
E1 THROUGH E2 ASSIGNED

10560891

```
=> e# and L3
E# IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s e1-2 and L13
             0 "142:75325"/AN
             1 "2004:1154700"/AN
L14          1 ("142:75325"/AN OR "2004:1154700"/AN) AND L13

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      18.58     549.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -1.56      -2.34

FILE 'REGISTRY' ENTERED AT 15:05:29 ON 16 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 MAY 2007  HIGHEST RN 934804-03-2
DICTIONARY FILE UPDATES:  15 MAY 2007  HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> tra rn
L15          TRANSFER L14 1- RN :      20 TERMS
L16          20 L15

=> d scan

L16  20 ANSWERS   REGISTRY  COPYRIGHT 2007 ACS on STN
IN   Pyridine, 2,6-dichloro-
MF   C5 H3 Cl2 N
CI   COM
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L16 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pyridine, 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI)
MF C35 H29 N O6
CI COM

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L16 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-ol, 4',4'''-[(6-methyl-2,4-pyrimidinediyl)bis(oxy)]bis- (9CI)
MF C29 H22 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L16 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-ol, 4'-[[6-(4-hydroxyphenoxy)-2-pyridinyl]oxy]- (9CI)
MF C23 H17 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L16 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,5-Naphthalenediamine, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI)
MF (C35 H29 N O6 . C10 H10 N2)x
CI PMS

CM 1

PAGE 1-A





PAGE 2-A



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L16 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Oxirane, 2,2'-[1,3-phenylenebis(methyleneoxy[1,1'-biphenyl]-4',4-diyloxymethylene)]bis- (9CI)
MF C38 H34 O6

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L16 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pyridazine, 3,6-dichloro-
MF C4 H2 Cl2 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d brow
:1-20

L16 ANSWER 1 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **815600-61-4** REGISTRY
ED Entered STN: 18 Jan 2005
CN Oxirane, 2,2'-[1,3-phenylenebis(methyleneoxy[1,1'-biphenyl]-4',4-diyloxymethylene)]bis- (9CI) (CA INDEX NAME)
MF C38 H34 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 2 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **815600-60-3** REGISTRY
ED Entered STN: 18 Jan 2005
CN [1,1'-Biphenyl]-4-ol, 4',4'''-[1,3-phenylenebis(methyleneoxy)]bis- (9CI) (CA INDEX NAME)
MF C32 H26 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 3 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **815600-59-0** REGISTRY
ED Entered STN: 18 Jan 2005
CN Benzenamine, 4,4'-methylenebis-, polymer with 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]pyridine (9CI) (CA INDEX NAME)
MF (C29 H25 N O6 . C13 H14 N2)x
CI PMS
PCT Epoxy resin, Polyether, Polyother
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 815600-56-7
CMF C29 H25 N O6



CM 2

CRN 101-77-9
CMF C13 H14 N2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 4 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **815600-58-9** REGISTRY
ED Entered STN: 18 Jan 2005
CN 1,5-Naphthalenediamine, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)
MF (C35 H29 N O6 . C10 H10 N2)x
CI PMS
PCT Epoxy resin, Polyether, Polyother
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 815600-49-8
CMF C35 H29 N O6

PAGE 1-A



PAGE 2-A



CM 2

CRN 2243-62-1
CMF C10 H10 N2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 5 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **815600-57-8** REGISTRY
ED Entered STN: 18 Jan 2005
CN Benzenamine, 4,4'-methylenebis-, polymer with 2,6-bis[[4'-

10560891

(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)
MF (C35 H29 N O6 . C13 H14 N2)x
CI PMS
PCT Epoxy resin, Polyether, Polyother
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 815600-49-8
CMF C35 H29 N O6

PAGE 1-A



PAGE 2-A



CM 2

CRN 101-77-9
CMF C13 H14 N2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 6 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **815600-56-7** REGISTRY
ED Entered STN: 18 Jan 2005
CN Pyridine, 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)
MF C29 H25 N O6
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 7 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **815600-55-6** REGISTRY
ED Entered STN: 18 Jan 2005
CN [1,1'-Biphenyl]-4-ol, 4'-[[6-(4-hydroxyphenoxy)-2-pyridinyl]oxy]- (9CI) (CA INDEX NAME)
MF C23 H17 N O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 8 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **815600-54-5** REGISTRY
ED Entered STN: 18 Jan 2005
CN [1,1'-Biphenyl]-4-ol, 4'-[(6-chloro-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)
MF C17 H12 Cl N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 9 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **815600-53-4** REGISTRY
ED Entered STN: 18 Jan 2005
CN Pyrimidine, 4-methyl-2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)
MF C35 H30 N2 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

PAGE 1-A



PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 10 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **815600-52-3** REGISTRY
ED Entered STN: 18 Jan 2005
CN [1,1'-Biphenyl]-4-ol, 4',4'''-[(6-methyl-2,4-pyrimidinediyl)bis(oxy)]bis- (9CI) (CA INDEX NAME)
MF C29 H22 N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 11 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **815600-51-2** REGISTRY
ED Entered STN: 18 Jan 2005
CN Pyridazine, 3,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)

10560891

MF C34 H28 N2 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 12 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **815600-50-1** REGISTRY
ED Entered STN: 18 Jan 2005
CN [1,1'-Biphenyl]-4-ol, 4',4'''-[3,6-pyridazinediylbis(oxy)]bis- (9CI) (CA INDEX NAME)
MF C28 H20 N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 13 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **815600-49-8** REGISTRY
ED Entered STN: 18 Jan 2005
CN Pyridine, 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)
MF C35 H29 N O6
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

PAGE 1-A





PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 14 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **30062-98-7** REGISTRY
ED Entered STN: 16 Nov 1984
CN [1,1'-Biphenyl]-4-ol, 4',4'''-[2,6-pyridinediylbis(oxy)]bis- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 4-Biphenylol, 4',4'''-(2,6-pyridinediyldioxy)di- (8CI)
MF C29 H21 N O4
LC STN Files: BEILSTEIN*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 15 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **5424-21-5** REGISTRY
ED Entered STN: 16 Nov 1984
CN Pyrimidine, 2,4-dichloro-6-methyl- (CA INDEX NAME)
OTHER NAMES:
CN 2,4-Dichloro-6-methylpyrimidine
CN 2,6-Dichloro-4-methylpyrimidine
CN 6-Methyl-2,4-dichloropyrimidine
CN NSC 13199
MF C5 H4 Cl2 N2
LC STN Files: AGRICOLA, BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, PS, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

190 REFERENCES IN FILE CA (1907 TO DATE)
193 REFERENCES IN FILE CAPLUS (1907 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L16 ANSWER 16 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **2402-78-0** REGISTRY
ED Entered STN: 16 Nov 1984
CN Pyridine, 2,6-dichloro- (CA INDEX NAME)
OTHER NAMES:
CN 2,6-Dichloropyridine
CN NSC 76606
MF C5 H3 Cl2 N
CI COM
LC STN Files: ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, DETHERM*, IFICDB, IFIPAT, IFIUDB, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

565 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
566 REFERENCES IN FILE CAPLUS (1907 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L16 ANSWER 17 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **626-16-4** REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzene, 1,3-bis(chloromethyl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN m-Xylene, α,α'-dichloro- (7CI, 8CI)
OTHER NAMES:
CN α,α'-Dichloro-m-xylene
CN 1,3-Bis(chloromethyl)benzene
CN m-Bis(chloromethyl)benzene
CN m-Xylene dichloride
CN m-Xylylene dichloride
CN NSC 96971
MF C8 H8 Cl2
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

265 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
265 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L16 ANSWER 18 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **141-30-0** REGISTRY
ED Entered STN: 16 Nov 1984
CN Pyridazine, 3,6-dichloro- (CA INDEX NAME)
OTHER NAMES:
CN 3,6-Dichloropyridazine
CN NSC 54498
MF C4 H2 Cl2 N2
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS,

CHEMINFORMRX, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

680 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
681 REFERENCES IN FILE CAPLUS (1907 TO DATE)
21 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L16 ANSWER 19 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **106-89-8** REGISTRY
ED Entered STN: 16 Nov 1984
CN Oxirane, 2-(chloromethyl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Oxirane, (chloromethyl)- (9CI)
CN Propane, 1-chloro-2,3-epoxy- (6CI, 8CI)
OTHER NAMES:
CN (±)-Epichlorohydrin
CN (Chloromethyl)ethylene oxide
CN (Chloromethyl)oxirane
CN (RS)-Epichlorhydrin
CN α-Epichlorohydrin
CN γ-Chloropropylene oxide
CN 1,2-Epoxy-3-chloropropane
CN 1-Chloro-2,3-epoxypropane
CN 2,3-Epoxypropyl chloride
CN 2-(Chloromethyl)oxirane
CN 3-Chloro-1,2-epoxypropane
CN 3-Chloro-1,2-propylene oxide
CN 3-Chloropropene-1,2-oxide
CN 3-Chloropropylene oxide
CN Chloropropylene oxide
CN dl-α-Epichlorohydrin
CN Epichlorohydrin
CN Glycerol epichlorohydrin
CN Glycidyl chloride
CN J 006
CN NSC 6747
DR 13403-37-7, 9009-12-5, 109351-74-8, 36250-81-4
MF C3 H5 Cl O
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

10560891



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

17384 REFERENCES IN FILE CA (1907 TO DATE)
4561 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
17416 REFERENCES IN FILE CAPLUS (1907 TO DATE)
27 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L16 ANSWER 20 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN **92-88-6** REGISTRY
ED Entered STN: 16 Nov 1984
CN [1,1'-Biphenyl]-4,4'-diol (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 4,4'-Biphenyldiol (8CI)
OTHER NAMES:
CN 4,4'-Biphenol
CN 4,4'-Bisphenol
CN 4,4'-Dihydroxy-1,1'-biphenyl
CN 4,4'-Dihydroxybiphenyl
CN 4,4'-Dihydroxydiphenyl
CN 4,4'-Diphenol
CN 4-(4-Hydroxyphenyl)phenol
CN Antioxidant DOD
CN ASM DOD
CN B 0464
CN BPL
CN BPL (phenol)
CN DOD
CN NSC 8711
CN p,p'-Biphenol
CN p,p'-Dihydroxybiphenyl
CN p,p'-Diphenol
CN p-Dihydroxydiphenyl
CN p-Diphenol
MF C12 H10 O2
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DETHERM*, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1982 REFERENCES IN FILE CA (1907 TO DATE)

10560891

145 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1987 REFERENCES IN FILE CAPLUS (1907 TO DATE)
34 REFERENCES IN FILE CAOLD (PRIOR TO 1967)
:end

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	42.15	604.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.34

FILE 'STNGUIDE' ENTERED AT 15:10:11 ON 16 MAY 2007

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 11, 2007 (20070511/UP).

=>
Connection closed by remote host

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptadko1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily

10560891

```
 NEWS 21  MAR 22  LWPI reloaded
 NEWS 22  MAR 30  RDISCLOSURE reloaded with enhancements
 NEWS 23  APR 02  JICST-EPLUS removed from database clusters and STN
 NEWS 24  APR 30  GENBANK reloaded and enhanced with Genome Project ID field
 NEWS 25  APR 30  CHEMCATS enhanced with 1.2 million new records
 NEWS 26  APR 30  CA/CAplus enhanced with 1870-1889 U.S. patent records
 NEWS 27  APR 30  INPADOC replaced by INPADOCDB on STN
 NEWS 28  MAY 01  New CAS web site launched
 NEWS 29  MAY 08  CA/CAplus Indian patent publication number format defined
 NEWS 30  MAY 14  RDISCLOSURE on STN Easy enhanced with new search and display
                  fields
 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:57:48 ON 16 MAY 2007

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 15:58:01 ON 16 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 MAY 2007  HIGHEST RN 934804-03-2
DICTIONARY FILE UPDATES:  15 MAY 2007  HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006
```

10560891

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10560891_resins2.str

chain nodes :
1 2 3 6 7 8
chain bonds :
1-2 1-8 2-3 3-6 6-7
exact/norm bonds :
1-8
exact bonds :
1-2 2-3 3-6 6-7

Match level :
1:CLASS 2:CLASS 3:CLASS 6:CLASS 7:CLASS 8:Atom
Generic attributes :
2:
Saturation : Unsaturated
3:
Saturation : Unsaturated

Element Count :
Node 2: Limited
C,C6

Node 3: Limited
C,C6

Node 8: Limited
C,C4-5
N,N1-2

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

10560891



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 15:58:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  1146945 TO ITERATE

  0.2% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:     22883318 TO 22994482
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 15:58:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 22943752 TO ITERATE

  1.1% PROCESSED   256670 ITERATIONS                               0 ANSWERS

  2.0% PROCESSED   452559 ITERATIONS                               0 ANSWERS

  2.8% PROCESSED   644587 ITERATIONS                               0 ANSWERS

  4.2% PROCESSED   956587 ITERATIONS                               2 ANSWERS

  4.4% PROCESSED  1000000 ITERATIONS                               2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.01.15

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:     22943752 TO 22943752
PROJECTED ANSWERS:              25 TO       65

L3             2 SEA SSS FUL L1

=> d scan

L3   2 ANSWERS   REGISTRY  COPYRIGHT 2007 ACS on STN
IN   1-Pyrrolidinepentanamide, 3-[(3'-hydroxy[1,1'-biphenyl]-3-yl)oxy]-
     δ,δ-dimethyl-α,α-diphenyl-, (3S)-
MF   C35 H38 N2 O3

Absolute stereochemistry.
```

10560891



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Pyrrolidinepentanamide, 3-[(3'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-δ,δ-dimethyl-α,α-diphenyl-, (3S)-
MF C35 H38 N2 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> 1
1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.45	173.66

FILE 'STNGUIDE' ENTERED AT 16:00:18 ON 16 MAY 2007

10560891

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 11, 2007 (20070511/UP).

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.24	173.90

FILE 'REGISTRY' ENTERED AT 16:02:24 ON 16 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2
DICTIONARY FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10560891_resin2.str





chain nodes :
1 2 3 6 7 8
chain bonds :
1-2 1-8 2-3 3-6 6-7
exact/norm bonds :
1-8
exact bonds :
1-2 2-3 3-6 6-7

10560891

Match level :
1:CLASS 2:CLASS 3:CLASS 6:CLASS 7:CLASS 8:Atom
Generic attributes :
2:
Saturation : Unsaturated
3:
Saturation : Unsaturated
8:
Saturation : Unsaturated

Element Count :
Node 2: Limited
C,C6

Node 3: Limited
C,C6

Node 8: Limited
C,C4-5
N,N1-2

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 16:02:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1146945 TO ITERATE

0.2% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 22883318 TO 22994482
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> FIL STNGUIDE

10560891

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.70	176.60

FILE 'STNGUIDE' ENTERED AT 16:05:42 ON 16 MAY 2007

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 11, 2007 (20070511/UP).

=>
=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.74	178.34

FILE 'REGISTRY' ENTERED AT 16:22:53 ON 16 MAY 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2
DICTIONARY FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\blahblah.str

10560891



chain nodes :
4 5 18
ring nodes :
1 2 3 6 7 8 9 10 11 12 13 14 15 16 17
chain bonds :
3-4 4-5 11-12
ring bonds :
1-2 1-3 2-3 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
1-2 1-3 2-3 3-4 4-5
exact bonds :
11-12
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17

Match level :
1:Atom 2:Atom 3:Atom 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:Atom
Generic attributes :
18:
Type of Ring System : Monocyclic

Element Count :
Node 18: Limited
C,C4-5
N,N1-2

L6 STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l6
SAMPLE SEARCH INITIATED 16:23:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     7347 TO ITERATE

 27.2% PROCESSED     2000 ITERATIONS                                  0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       141802 TO   152078
PROJECTED ANSWERS:               0 TO        0

L7            0 SEA SSS SAM L6

=> s l6 full
FULL SEARCH INITIATED 16:23:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   145946 TO ITERATE

100.0% PROCESSED   145946 ITERATIONS                                  3 ANSWERS
SEARCH TIME: 00.00.02

L8            3 SEA SSS FUL L6

=> d scan

L8   3 ANSWERS   REGISTRY  COPYRIGHT 2007 ACS on STN
IN   Pyrimidine, 5-octyl-2-[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]-, (R)-
     (9CI)
MF   C27 H32 N2 O2

Absolute stereochemistry.
```

10560891

ring/chain bonds :
2-5 3-6 11-12
exact/norm bonds :
1-2 1-3 2-5 3-6 11-12
exact bonds :
5-9 9-11

Match level :
1:Atom 2:CLASS 3:CLASS 5:Atom 6:Atom 9:Atom 11:CLASS 12:CLASS
Generic attributes :
5:
Saturation   : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System   : Monocyclic
6:
Saturation   : Unsaturated
Type of Ring System   : Monocyclic
9:
Saturation   : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System   : Monocyclic

Element Count :
Node 1: Limited
    C,C4-5
    N,N1-2

Node 5: Limited
    C,C6

Node 6: Limited
    C,C6

Node 9: Limited
    C,C6

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
GENERIC GROUP NOT VALID HERE
Generic groups may not be used in these circumstances:

1. Any generic group node (e.g., Hy) in a ring.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pyrimidine, 2-[4'-[(3-butyloxiranyl)methoxy][1,1'-biphenyl]-4-yl]-5-octyl-, (2S-trans)- (9CI)
MF C31 H40 N2 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pyrimidine, 5-octyl-2-[4'-[(3-propyloxiranyl)methoxy][1,1'-biphenyl]-4-yl]-, (2S-trans)- (9CI)
MF C30 H38 N2 O2

Absolute stereochemistry.

10560891



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>
Uploading C:\Program Files\Stnexp\Queries\crud.str



chain nodes :
4 5 18 20
ring nodes :
1 2 3 6 7 8 9 10 11 12 13 14 15 16 17
chain bonds :
3-4 4-5 11-12 18-20
ring bonds :
1-2 1-3 2-3 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
1-2 1-3 2-3 3-4 4-5 18-20
exact bonds :
11-12
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17

Match level :
1:Atom 2:Atom 3:Atom 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS
21:Atom
Generic attributes :
18:
Type of Ring System : Monocyclic